
Amgen Inc.
AMGNHealthcare|Drug Manufacturers - General|US
$460.42
+0.14 (+0.03%)
DCF Value
$902.10
Graham Number
$101.79
Cash / Share
$24.38
Clinical Trials (542)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06180278 Long-term, Open-label, Safety Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD) | Neuromyelitis Optica Spectrum Disorder | P4 | Active | 32 | Open-label | Inebilizumab |
| NCT04951856 Evolocumab or Normal Strategies to Reach LDL Objectives in Acute Myocardial Infarction Upbound to PCI | STEMI - ST Elevation Myocardial Infarction, NSTEMI - Non-ST Segment Elevation MI | P4 | Active | 2,166 | RCT, Open-label | Evolocumab 140 MG/ML, Standard of care (SOC) |
| NCT07866066 Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 Diabetes | Diabetes Mellitus, Type 2 | P3 | Recruiting | 1,300 | RCT, Open-label | Maridebart cafraglutide, Semaglutide |
| NCT07684235 Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION) | Obesity, Overweight | P3 | Recruiting | 3,200 | RCT, Double-blind | Maridebart cafraglutide, Placebo |
| NCT07005128 A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC) | Small-cell Lung Cancer, Extensive Stage Small-cell Lung Cancer | P3 | Active | 350 | RCT, Open-label | Tarlatamab, Durvalumab, Carboplatin, Etoposide |
| NCT03969329 A Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving Hemodialysis | Secondary Hyperparathyroidism | P3 | Recruiting | 24 | Open-label | Etelcalcetide |
| NCT05920356 A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202) | Non-Small Cell Lung Cancer (NSCLC) | P3 | Recruiting | 750 | RCT, Open-label | Sotorasib, Pembrolizumab |
| NCT06321601 Study to Evaluate Avacopan in Combination With a Rituximab or Cyclophosphamide-containing Regimen, in Children From 6 Years to < 18 Years of Age With AAV. | Vasculitis | P3 | Active | 19 | Open-label | Avacopan |
| NCT04528082 Apremilast Pediatric Study in Children With Active Oral Ulcers Associated With Behçet's Disease | Behçet Disease | P3 | Recruiting | 60 | RCT, Double-blind | Apremilast, Placebo |
| NCT06248619 A Trial to Investigate Teprotumumab Subcutaneous Administration Compared With Placebo in Male and Female Adult Participants With Moderate-to-severe Active Thyroid Eye Disease | Thyroid Eye Disease | P3 | Active | 89 | RCT, Double-blind | Teprotumumab |
| NCT06858878 Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight | P3 | Active | 1,105 | RCT, Double-blind | Maridebart cafraglutide, Placebo |
| NCT07293260 Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction - Coronary Computed Tomography Angiography Trial | Cardiovascular Disease | P3 | Recruiting | 406 | RCT, Double-blind | Olpasiran, Placebo |
| NCT07225686 Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy | Obesity, Obstructive Sleep Apnea | P3 | Active | 250 | RCT, Double-blind | Maridebart cafraglutide, Placebo |
| NCT07778316 Phase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC) | Small Cell Lung Cancer | P3 | Recruiting | 400 | RCT, Open-label | Tarlatamab |
| NCT06883305 A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006) | Chronic Obstructive Pulmonary Disease (COPD) | P3 | Recruiting | 990 | RCT, Double-blind | Tezepelumab |
| NCT06691984 Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute) | Metastatic Castration-resistant Prostate Cancer | P3 | Active | 707 | RCT, Open-label | Xaluritamig, Abiraterone, Enzalutamide, Cabazitaxel |
| NCT06054555 A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma | Melanoma | P3 | Active | 633 | RCT, Double-blind | ABP 206, Nivolumab |
| NCT07851220 A Phase 3 Study of Inebilizumab in Participants With Primary Membranous Nephropathy | Glomerulonephritis, Membranous | P3 | Recruiting | 159 | RCT, Open-label | Inebilizumab, Tacrolimus |
| NCT03633708 A Trial of Etelcalcetide in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis | Secondary Hyperparathyroidism, Chronic Kidney Disease | P3 | Recruiting | 56 | RCT, Open-label | Etelcalcetide |
| NCT03289299 Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant | Smoldering Multiple Myeloma | P2 | Active | 87 | Open-label | Carfilzomib, Lenalidomide, Daratumumab, Dexamethasone |
| NCT05074810 Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients | Non Small Cell Lung Cancer, KRAS Activating Mutation | P1P2 | Active | 153 | Open-label | avutometinib and sotorasib, avutometinib and sotorasib and defactinib |
| NCT05848687 TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II | Lymphoblastic Leukemia | P1P2 | Recruiting | 90 | Open-label | Dexamethasone, Mitoxantrone, PEG asparaginase, Bortezomib, Vorinostat, Mercaptopurine, Methotrexate, Blinatumomab, Ziftomenib |
| NCT02925234 The Drug Rediscovery Protocol (DRUP Trial) | Cancer, Tumors | P2 | Recruiting | 1,550 | Open-label | Panitumumab, Olaparib, Dabrafenib, Nilotinib, Trametinib, Erlotinib, Trastuzumab and Pertuzumab (combination treatment), Vemurafenib and Cobimetinib (combination treatment), Vismodegib, Regorafenib, Nivolumab, Afatinib, Dabrafenib and trametinib, Ribociclib, Lenvatinib, Pembrolizumab, Durvalumab, Rucaparib, Axitinib, Palbociclib, Crizotinib, Sunitinib, Cabozantinib, Abemaciclib, Alectinib, Atezolizumab and Bevacizumab, Ipilimumab and nivolumab, Entrectinib, Talazoparib, Dacomitinib, Lorlatinib, Erdafitinib, Alpelisib, Niraparib, Pemigatinib, Selpercatinib, Tepotinib |
| NCT06529731 Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes Post Allogeneic Hematopoietic Stem Cell Transplantation | Acute Myeloid Leukemia, Myelodysplastic Syndromes | P2 | Recruiting | 57 | Open-label | Interferon gamma-1b, Donor Leukocyte Infusion (DLI) |
| NCT03114865 A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance | Acute Lymphoblastic Leukemia, B-cell Non Hodgkin Lymphoma | P1P2 | Active | 44 | Open-label | Blinatumomab 9ug, Blinatumomab 28 ug, Blinatumomab, Dexamethasone |
| NCT06680622 Bemarituzumab in FGFR2b+ Patients With Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction, Who Failed at Least One Prior Line of Palliative Chemotherapy | Metastatic Gastro-esophageal Adenocarcinoma | P2 | Active | 126 | Open-label | bemarituzumab, paclitaxel, ramucirumab, bemarituzumab, irinotecan, bemarituzumab, trifluridine/tipiracil |
| NCT07172919 A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation | Advanced Solid Tumors | P2 | Recruiting | 14 | Open-label | Sotorasib, Panitumumab |
| NCT05060016 A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC) | Relapsed/Refractory Small Cell Lung Cancer | P2 | Active | 222 | RCT, Open-label | Tarlatamab |
| NCT02415413 Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple Myeloma | Smoldering Multiple Myeloma | P2 | Active | 90 | Open-label | carfilzomib, Lenalidomide, Dexamethasone, Melphalan |
| NCT04176718 Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM | Multiple Myeloma, Refractory Multiple Myeloma | P2 | Active | 44 | Open-label | Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone |
| NCT06660810 Neoadjuvant Intralesional Injection of Talimogene Laherparepvec | Soft Tissue Sarcoma, Sarcoma,Soft Tissue | P2 | Active | 2 | Open-label | Talimogene Laherparepvec |
| NCT04599062 TVEC and Preop Radiation for Sarcoma (8 ml Dose) | Soft Tissue Sarcoma | P1P2 | Active | 8 | Open-label | Talimogene Laherparepvec |
| NCT05789303 Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma | Multiple Myeloma, Relapse Multiple Myeloma | P2 | Recruiting | 83 | Open-label | Belantamab mafodotin, Carfilzomib, Pomalidomide, Dexamethasone |
| NCT07441252 A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight | Overweight or Obesity and Elevated Liver Fat | P2 | Active | 180 | RCT, Double-blind | Maridebart cafraglutide, Placebo |
| NCT06570798 A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases | Systemic Lupus Erythematosus, Active Refractory Rheumatoid Arthritis | P2 | Recruiting | 220 | Open-label | Inebilizumab, Blinatumomab |
| NCT06401044 A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease | Thyroid Eye Disease | P1P2 | Active | 94 | RCT, Double-blind | AMG 732 |
| NCT03500445 Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma | Myeloma, Multiple Myeloma | P2 | Active | 75 | Open-label | Daratumumab, Carfilzomib, Lenalidomide, Dexamethasone |
| NCT06593522 A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201) | MTAP-deleted NSCLC | P2 | Active | 61 | RCT, Open-label | anvumetostat |
| NCT04822337 Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma | Multiple Myeloma | P1P2 | Recruiting | 70 | Open-label | Carfilzomib, Lenalidomide, Dexamethasone, Belantamab Mafodotin |
| NCT07037758 A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311) | Extensive Stage Small Cell Lung Cancer | P1 | Recruiting | 380 | Open-label | Tarlatamab, AB248 |
| NCT07531095 Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC) | Small Cell Lung Cancer | P1 | Recruiting | 160 | Open-label | ZL-1310, Tarlatamab, Durvalumab |
| NCT07493512 Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer | Metastatic Castration-resistant Prostate Cancer (mCRPC) | P1 | Recruiting | 40 | Open-label | Xaluritamig |
| NCT07160257 A Study to Evaluate the Effect of Maridebart Cafraglutide on Insulin Sensitivity and β-cell Function in Participants With Type 2 Diabetes Mellitus | Type 2 Diabetes Mellitus | P1 | Active | 56 | RCT, Double-blind | Maridebart cafraglutide, Placebo |
| NCT05361395 First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC) | Extensive Stage Small Cell Lung Cancer | P1 | Active | 184 | Open-label | Tarlatamab, Carboplatin, Etoposide, Atezolizumab, Durvalumab |
| NCT07297979 Evaluation of Xaluritamig in Adults, Adolescents and Children With Relapsed or Refractory Ewing Sarcoma (EWS) | Ewing Sarcoma | P1 | Recruiting | 50 | Open-label | Xaluritamig |
| NCT04221542 Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer | Prostate Cancer | P1 | Recruiting | 479 | RCT, Open-label | AMG 509, Abiraterone, Enzalutamide |
| NCT07094113 AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors | KRAS Altered Advanced or Metastatic Solid Tumors | P1 | Recruiting | 434 | Open-label | AMG 410, Pembrolizumab, Panitumumab |
| NCT07102394 Feasibility and Tolerability of IMLYGIC for the Treatment of Cutaneous Neurofibromas in Adults With NF1 | NF1, Neurofibromatosis | P1 | Recruiting | 10 | Open-label | Imlygic |
| NCT06898957 Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC) | Small Cell Lung Cancer | P1 | Active | 29 | Open-label | YL201, Tarlatamab, Durvalumab |
| NCT07811999 Comparing the Extent to Which Romosozumab (AMG 785) is Made Available in the Body When Administered as a Single SC Injection or as 2 SC Injections | Healthy Participants | P1 | Recruiting | 308 | RCT, Open-label | Romosozumab |
| NCT07745907 A Phase 1 Trial of AMG 691 in Healthy Chinese and Japanese Volunteers | Healthy Participants | P1 | Recruiting | 28 | RCT, Open-label | AMG 691 |
| NCT07013578 TIDHI Mental Health in IBD Patients Study | Crohn Disease (CD), Ulcerative Colitis (UC) | N/A | Recruiting | 100 | RCT, Open-label | — |
| NCT04151342 CAnadian CAncers With Rare Molecular Alterations (CARMA) - Basket Real-world Observational Study (BROS) | Cancer, Malignancies Multiple | Recruiting | 5,500 | — | Cancer treatment with tyrosine kinase inhibitors (TKIs) or other molecularly targeted therapeutic agents. | |
| NCT01277419 German Spondyloarthritis Inception Cohort | Ankylosing Spondylitis (AS) / Radiographic Axial SpA (r-axSpA), Non-radiographic Axial Spondyloarthritis (Nr-axSpA) | Recruiting | 1,000 | — | — | |
| NCT02009345 Familial Hypercholesterolemia Canada / Hypercholesterolemie Familiale Canada | Familial Hypercholesterolemia, Lipid Disorder | Recruiting | 6,000 | — | — | |
| NCT01848028 PsoBest - The German Psoriasis Registry | Psoriasis, Psoriatic-arthritis | Recruiting | 3,500 | — | — | |
| NCT02622581 Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients | Metastatic Non-small Cell Lung Cancer (NSCLC), Non-small Cell Lung Cancer Metastatic | Recruiting | 14,500 | — | — | |
| NCT05001087 A "Physician & Patient-powered" Cohort Registry (MY MYELOMA) | Multiple Myeloma | Recruiting | 1,900 | — | — | |
| NCT07478887 Impact of the Corrie Lipids Digital Health Program on Lipid Optimization | Cardiovascular Risk, LDL-C | N/A | Recruiting | 1,000 | Open-label | — |
| NCT05885607 Early Metabolic Adaptations to SGLT2 Inhibition in Heart Failure | Heart Failure NYHA Class II, Heart Failure NYHA Class III | Active | 40 | — | — | |
| NCT06295679 A Study Assessing Repatha® in Combination With Standard of Care (SOC) Compared With SOC on Major Cardiovascular Events in Chinese Participants With Atherosclerotic Cardiovascular Disease | Major Cardiovascular Event, Established Atherosclerotic Cardiovascular Disease | Active | 7,000 | — | — | |
| NCT06471036 Test 2 Treat: Can we Improve the Testing and Treatment of High Cholesterol in Patients Who Have Been Hospitalized for a Cardiac Event by Providing Education to Doctors and Patients? | ASCVD, LDL-C | N/A | Recruiting | 400 | RCT, Open-label | — |
| NCT05909761 Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® During Pregnancy | Neuromyelitis Optica Spectrum Disorder, Pregnancy Related | Recruiting | 60 | — | UPLIZNA | |
| NCT03168529 Trial Assessing the Effectiveness of Ivabradine Started at Discharge From the Observation Unit | Heart Failure | P4 | Terminated | 19 | RCT, Double-blind | Ivabradine, Placebo |
| NCT00640393 Safety and Efficacy of Combining nbUVB to Etanercept in Patients | Psoriasis Vulgaris | P4 | Completed | 99 | RCT, Single-blind | Etanercept |
| NCT03851263 Multislice Computed Tomography Assessment of PCSK9 Inhibition on Coronary Perfusion | Coronary Artery Disease | P4 | Withdrawn | — | Open-label | Evolocumab |
| NCT00967538 Safety and Efficacy of Etanercept in Patients With Psoriasis Who Failed to Respond to Other Biologic Treatments | Psoriasis | P4 | Completed | 89 | Open-label | etanercept 50 mg |
| NCT04252742 Erenumab - Comprehensive Assessment of Efficacy in (High-Frequency) Episodic Migraine | Migraine | P4 | Completed | 512 | RCT, Double-blind | Erenumab, Placebo |
| NCT02749370 Study to Evaluate the Efficacy of Etanercept Treatment in Adults Who Failed Therapy With Apremilast | Plaque Psoriasis | P4 | Completed | 80 | Open-label | Etanercept |
| NCT03331666 Impact of LDL-cholesterol Lowering on Platelet Activation | Familial Hypercholesterolemia | P4 | Terminated | 4 | RCT, Double-blind | Evolocumab |
| NCT00791765 Moderate to Severe Plaque Psoriasis With Scalp Involvement | Psoriasis | P4 | Completed | 124 | RCT, Double-blind | Etanercept, Placebo |
| NCT02346877 Evaluate Effects of Personalized Patient Counselling for Enbrel® Therapy in Adults With Rheumatoid Arthritis | Persistence to Enbrel | P4 | Terminated | 19 | Open-label | — |
| NCT00094341 Preference of Rheumatoid Arthritis (RA) Patients of Enbrel® (Etanercept) Auto-Injector Versus Enbrel® Pre-Filled Syringes | Rheumatoid Arthritis | P4 | Completed | 215 | RCT, Open-label | Etanercept |
| NCT03087851 Treatment With Zoledronic Acid Subsequent to Denosumab in Osteoporosis | Osteoporosis | P4 | Completed | 61 | RCT, Open-label | Zoledronic Acid |
| NCT00332332 Canadian Assessment of Patient Outcomes and Effectiveness of Etanercept (Enbrel) in Psoriasis | Psoriasis | P4 | Completed | 246 | Open-label | etanercept |
| NCT01563185 Open-label Safety and Pharmacokinetic Study of DUEXIS® (Ibuprofen and Famotidine) Tablets in Juvenile Idiopathic Arthritis | Juvenile Idiopathic Arthritis | P4 | Completed | 12 | Open-label | 800 mg ibuprofen/26.6 mg famotidine |
| NCT04772313 Pegloticase and Methotrexate Co-administered in Participants With Uncontrolled Gout Who Previously Failed Pegloticase Monotherapy | Uncontrolled Gout | P4 | Completed | 11 | Open-label | Pegloticase, Methotrexate (MTX) |
| NCT00111124 Enbrel® in Psoriatic Arthritis | Psoriasis | P4 | Completed | — | — | Enbrel® |
| NCT01543204 Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab | Psoriasis | P4 | Terminated | 64 | Open-label | Etanercept |
| NCT03456856 A Study of Ivabradine in African-American/ Black Subjects With Heart Failure and Left Ventricular Systolic Dysfunction. | Heart Failure (HF) | P4 | Completed | 30 | Open-label | Ivabradine |
| NCT04506086 Feasibility Study to Evaluate Outpatient Blinatumomab in Subjects With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (ALL) | B-precursor Acute Lymphoblastic Leukemia | P4 | Terminated | 10 | Open-label | Blinatumomab |
| NCT02101164 Evaluate Time Associated With the Preparation & Administration of Denosumab/Pamidronate in Patients With Solid Tumors and Metastatic Bone Disease | Solid Tumor, Metastatic Bone Disease | P4 | Withdrawn | — | RCT, Open-label | denosumab, pamidronate |
| NCT03994731 Study of KRYSTEXXA® (Pegloticase) Plus Methotrexate in Participants With Uncontrolled Gout | Gout | P4 | Completed | 152 | RCT, Double-blind | Pegloticase, methotrexate, placebo, gout flare prophylaxis regimen, fexofenadine, acetaminophen, methylprednisolone |
| NCT03301857 Long-term Safety Follow-up of Subjects With Giant Cell Tumor of Bone Treated With Denosumab in Study 20062004 | Giant Cell Tumor of Bone | P4 | Completed | 85 | Open-label | Denosumab |
| NCT04306081 Effect of Evolocumab in Functional Status and LDL Oxidation of Patients With Peripheral Arterial Disease | Peripheral Arterial Disease | P4 | Unknown | 86 | RCT, Double-blind | Evolocumab 140 mg/mL Subcutaneous Injection 1 milliliter (mL) pre-filled injector Pen x 3 for a monthly dose of 420 mg for 6 months. |
| NCT03912337 Effect of Erenumab-aooe on Disability and Work Productivity in Employed Subjects With Episodic Migraine | Migraine | P4 | Terminated | 29 | RCT, Double-blind | Placebo, Erenumab |
| NCT00127842 REPArE: Rating Evaluations in Psoriatic Arthritis (PsA) With Etanercept (Enbrel®) | Psoriatic Arthritis | P4 | Completed | 110 | Open-label | Etanercept |
| NCT00277160 A Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis After Chemotherapy in Elderly Subjects (>/= 65 Years Old) With Cancer | Neutropenia, Breast Cancer | P4 | Completed | 852 | RCT, Open-label | Neulasta (pegfilgrastim) |
| NCT03335488 Study of Glycerol Phenylbutyrate & Sodium Phenylbutyrate in Phenylbutyrate Naïve Patients With Urea Cycle Disorders (UCDs) | Urea Cycle Disorder | P4 | Completed | 16 | RCT, Open-label | RAVICTI, NaPBA |
| NCT00259610 Treatment of Early Aggressive Rheumatoid Arthritis (TEAR) | Rheumatoid Arthritis | P4 | Completed | 755 | RCT, Double-blind | methotrexate, sulfasalazine, hydroxychloroquine, etanercept |
| NCT00833729 The Safety & Efficacy of Etanercept in Psoriasis Patients Who Have Not Responded to Adalimumab | Plaque Psoriasis | P4 | Completed | 10 | Open-label | etanercept |
| NCT00803712 20070360 Incident Dialysis | Chronic Kidney Disease, Secondary Hyperparathyroidism | P4 | Completed | 313 | RCT, Open-label | Cinacalcet, Vitamin D |
| NCT00121433 Leptin and Endothelial Function | Healthy | P4 | Completed | 15 | RCT, Double-blind | leptin |
| NCT07803679 A Trial Assessing the Effectiveness of Evolocumab in Reducing the Plaque Burden in Participants With Subclinical Atheroma | Coronary Artery Disease, Hypercholesterolemia | P4 | Not Yet Recruiting | 308 | RCT, Single-blind | Evolocumab, Routine Lipid Management |
| NCT01009879 Human Tumor Necrosis Factor Alpha (TNFa)-Induced Pre-B Cell Bone Marrow Emigrants | Rheumatoid Arthritis | P4 | Withdrawn | — | Open-label | Etanercept |
| NCT00111995 Evaluating Aranesp® for the Treatment of Anemia in African-American Subjects With Chronic Renal Failure (CRF) Receiving Hemodialysis | Chronic Renal Failure, Anemia | P4 | Completed | 400 | RCT, Double-blind | Aranesp® |
| NCT00153868 A Web-based Study of Quality of Life Benefits Associated Aranesp in Anemic Patients With Cancer | Anemia, Cancer | P4 | Completed | 43 | Open-label | darbepoetin alfa |
| NCT00132418 Study of Enbrel in Rheumatoid Arthritis (RA) Subjects With Comorbid Disorders | Rheumatoid Arthritis | P4 | Completed | 564 | RCT, Double-blind | Enbrel, Placebo |
| NCT04249427 Erenumab for Idiosyncratic Facial Pain | Facial Pain, Rhinosinusitis | P4 | Completed | 29 | RCT, Double-blind | Erenumab Prefilled Syringe |
| NCT00353119 A Placebo-Controlled Double-Blind Study on the Safety and Efficacy of Etanercept in Palmoplantar Pustulosis | Palmoplantaris Pustulosis | P3 | Completed | 15 | RCT, Double-blind | Placebo comparator, Etanercept |
| NCT03029234 Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Relapsed & Refractory Multiple Myeloma | Relapsed and Refractory Multiple Myeloma | P3 | Completed | 126 | Open-label | Dexamethasone, Carfilzomib |
| NCT01966003 Efficacy and Safety Study of ABP 215 Compared With Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | P3 | Completed | 642 | RCT, Double-blind | Carboplatin, Paclitaxel, ABP 215, Bevacizumab |
| NCT02126449 DIetary REstriction as an Adjunct to Neoadjuvant ChemoTherapy for HER2 Negative Breast Cancer | Fasting Mimicking Diet, Breast Cancer | P2P3 | Completed | 131 | RCT, Open-label | — |
| NCT01901146 Efficacy and Safety Study of ABP 980 Compared With Trastuzumab in Women With HER2-positive Early Breast Cancer | Breast Cancer | P3 | Completed | 725 | RCT, Double-blind | ABP 980, Trastuzumab, Paclitaxel |
| NCT01652872 Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease | Anemia in Chronic Kidney Disease Patients Not on Dialysis | P3 | Completed | 756 | RCT, Double-blind | Darbepoetin alfa |
| NCT05062759 Study to Assess the Effect of Tezepelumab on the Immune Response to Influenza Vaccination in Participants With Asthma | Moderate to Severe Asthma | P3 | Completed | 70 | RCT, Double-blind | Tezepelumab, Placebo |
| NCT01568866 Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients | Multiple Myeloma | P3 | Completed | 929 | RCT, Open-label | Carfilzomib, Bortezomib, Dexamethasone |
| NCT01697072 First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma | Gastric Cancer | P3 | Terminated | 609 | RCT, Double-blind | Rilotumumab, Epirubicin, Cisplatin, Capecitabine |
| NCT06224192 A Study With Self-administered Rocatinlimab in Adolescent and Adult Participants With Moderate-to-severe Atopic Dermatitis | Atopic Dermatitis | P3 | Completed | 151 | RCT, Open-label | — |
| NCT05882877 A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) | Atopic Dermatitis | P3 | Terminated | 2,621 | RCT, Double-blind | Rocatinlimab |
| NCT01925768 Safety and Efficacy Study of Apremilast to Treat Psoriatic Arthritis | Psoriatic Arthritis | P3 | Completed | 219 | RCT, Double-blind | Apremilast 30 mg, Placebo |
| NCT01849497 Study to Assess In-home Use of Evolocumab (AMG 145) Using a Prefilled Syringe or a Prefilled Autoinjector/Pen | Primary Hypercholesterolemia, Mixed Dyslipidemia | P3 | Completed | 149 | RCT, Open-label | Evolocumab Pre-filled Syringe, Evolocumab AI/pen |
| NCT03300609 5-FU Based Maintenance Therapy in RAS Wild Type Metastatic Colorectal Cancer After Induction With FOLFOX Plus Panitumumab | Colorectal Adenocarcinoma, RAS Wild Type | P3 | Terminated | 4 | RCT, Open-label | Panitumumab, Oxaliplatin, Leucovorin Calcium, Fluorouracil, Capecitabine |
| NCT02016716 A Randomized Phase 3 Study to Evaluate Two Formulations of Romosozumab in Postmenopausal Women With Osteoporosis | Postmenopausal Osteoporosis | P3 | Completed | 294 | RCT, Double-blind | Romosozumab 90 mg/mL, Placebo 90 mg/mL, Romosozumab 70 mg/mL, Placebo 70 mg/mL |
| NCT01180634 MP-376 (Aeroquin™, Levofloxacin for Inhalation) in Patients With Cystic Fibrosis | Cystic Fibrosis | P3 | Completed | 330 | RCT, Double-blind | Aeroquin, Placebo |
| NCT01161498 Study of Safety and Efficacy of Talimogene Laherparepvec With Cisplatin and Radiotherapy for Treatment of Locally Advanced Head and Neck Cancer | Squamous Cell Carcinoma, Head and Neck Cancer | P3 | Terminated | 5 | RCT, Open-label | Talimogene Laherparepvec, Cisplatin |
| NCT00116701 Treatment for Subjects With Chronic Kidney Disease Receiving Haemodialysis | Kidney Disease | P3 | Completed | 200 | Open-label | Aranesp® |
| NCT01302392 A Study of Carfilzomib vs Best Supportive Care in Subjects With Relapsed and Refractory Multiple Myeloma | Multiple Myeloma | P3 | Completed | 315 | RCT, Open-label | Carfilzomib, Best Supportive Care |
| NCT02792699 Study to Assess if ABP 798 is Safe & Effective in Treating Moderate to Severe Rheumatoid Arthritis (RA) Compared to Rituximab | Arthritis, Rheumatoid | P3 | Completed | 311 | RCT, Double-blind | ABP 798, Rituximab (US), Rituximab (EU) |
| NCT00925600 Evaluation of New or Worsening Lens Opacifications in Men With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss | Cancer, Cataract | P3 | Completed | 769 | RCT, Double-blind | Denosumab, Placebo |
| NCT03832998 Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine | Migraine | P3 | Completed | 284 | RCT, Double-blind | Erenumab Dose 1, Erenumab Dose 2, Erenumab Dose 3 |
| NCT01196715 Comparison Study of Standard Care Against Combination of Growth Factors Agents for Low-risk Myelodysplastic Syndromes | Myelodysplastic Syndrome | P3 | Completed | 360 | RCT, Open-label | Darbepoetin alpha, Filgrastim |
| NCT00980174 Study to Compare the Efficacy and Safety of DenosumAb Versus Placebo in Males With Osteoporosis | Low Bone Mass, Low Bone Mineral Density | P3 | Completed | 242 | RCT, Double-blind | 60 mg denosumab |
| NCT00111111 An Evaluation of Etanercept in the Treatment of Subjects With Psoriasis | Psoriasis | P3 | Completed | — | RCT, Open-label | Etanercept |
| NCT00950911 Open Label Extension to SRE Studies in United Kingdom and Czech Republic Only | Bone Metastases in Men With Hormone-Refractory Prostate Cancer, Bone Metastases in Subjects With Advanced Breast Cancer | P3 | Completed | 35 | Open-label | amg 162 |
| NCT00144755 R-CHOP-14 Versus R-CHOP-21 and Darbepoetin Alpha in Patients Aged 60-80 Years With Diffuse Large B-cell Lymphoma | Diffuse Large Cell Lymphoma | P3 | Completed | 600 | RCT, Open-label | Darbepoetin alfa |
| NCT00089791 A Study to Evaluate Denosumab in the Treatment of Postmenopausal Osteoporosis | Osteoporosis | P3 | Completed | 7,808 | RCT, Double-blind | placebo, Denosumab |
| NCT00936897 A Study to Evaluate the Safety and Efficacy of Denosumab and Ibandronate in Postmenopausal Women Sub-Optimally Treated With Daily or Weekly Bisphosphonates | Postmenopausal Osteoporosis | P3 | Completed | 833 | RCT, Open-label | Ibandronate, Denosumab |
| NCT03706079 Extension Study to Evaluate the Safety and Tolerability of Tezepelumab in Adults and Adolescents With Severe, Uncontrolled Asthma | Asthma | P3 | Completed | 951 | RCT, Double-blind | Tezepelumab |
| NCT00557817 Erythropoietin (Epo) and Venofer Trial After Autologous Hematopoietic Stem Cell Transplantation (HSCT) | Hematological Malignancies | P2P3 | Completed | 125 | RCT, Open-label | Darbepoetin alpha (Aranesp), Iron saccharate (Venofer) |
| NCT03930186 A Phase 3B, Open-label, Single-arm Study of the Efficacy and Safety of Apremilast, in Subjects With Plaque Psoriasis That is Not Adequately Controlled by Topical Therapy | Plaque Psoriasis | P3 | Completed | 152 | Open-label | Apremilast, Topical Therapy |
| NCT01763827 Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2 | Hyperlipidemia | P3 | Completed | 615 | RCT, Double-blind | Evolocumab, Ezetimibe, Placebo to Evolocumab |
| NCT07637513 Tarlatamab and Durvalumab vs. Durvalumab Alone for Limited-Stage-Small Cell Lung Cancer | Limited Stage Small-Cell Lung Cancer | P3 | Not Yet Recruiting | 430 | RCT, Open-label | Tarlatamab, Durvalumab |
| NCT06122649 A Study to Investigate Efficacy and Safety of Apremilast 30 mg Twice Daily (BID) in Chinese Participants With Moderate to Severe Plaque-type Psoriasis (PsO) | Plaque Psoriasis | P3 | Completed | 203 | RCT, Double-blind | apremilast, Placebo |
| NCT00785421 Chemotherapy With or Without Enoxaparin in Pancreatic Cancer | Pancreatic Cancer | P2P3 | Completed | 312 | RCT, Open-label | enoxaparin, chemotherapy with LMWH - enoxaparin, only chemotherapy |
| NCT00111137 Treatment for Patients With Non-Myeloid Malignancies Receiving Chemotherapy | Cancer, Non-Myeloid Malignancies | P3 | Completed | 718 | RCT, Open-label | rHuEPO, Darbepoetin alfa |
| NCT01493505 TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer | Fallopian Tube Cancer, Ovarian Cancer | P3 | Terminated | 1,015 | RCT, Double-blind | AMG 386, Paclitaxel, AMG 386 Placebo, Carboplatin |
| NCT02352753 Multicenter,Single-arm Study to Evaluate Efficacy, Safety, & Pharmacokinetics of Denosumab in Children w/ OI | Osteogenesis Imperfecta | P3 | Terminated | 153 | Open-label | Denosumab |
| NCT03811418 A Study to Compare Pertuzumab + Trastuzumab + Vinorelbine vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-positive Metastatic Breast Cancer | Advanced Breast Cancer, HER2-positive Breast Cancer | P3 | Withdrawn | — | RCT, Open-label | Trastuzumab, Pertuzumab, Vinorelbine, Docetaxel |
| NCT00523341 Extension Study to Evaluate the Long Term Safety and Efficacy of Denosumab in the Treatment of Osteoporosis | Osteopenia, Osteoporosis | P3 | Completed | 4,550 | Open-label | Denosumab |
| NCT02797080 Long-Term Safety Extension Study of ACTIMMUNE® (Interferon γ-1b) in Children and Young Adults With Friedreich's Ataxia | Friedreich's Ataxia | P3 | Completed | 38 | Open-label | interferon γ-1b |
| NCT01281254 AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2) | Fallopian Tube Cancer, Ovarian Cancer | P3 | Terminated | 223 | RCT, Double-blind | AMG386 plus PLD, Placebo plus PLD |
| NCT02189837 Effects on Lipoprotein Metabolism From PCSK9 Inhibition Utilizing a Monoclonal Antibody | Primary Hyperlipidemia and Mixed Dyslipidemia | P3 | Completed | 89 | RCT, Double-blind | Evolocumab, Atorvastatin, Placebo to Evolocumab, Placebo to Atorvastatin |
| NCT02175277 Darbepoetin Alfa MDS Companion Protocol | Myelodysplastic Syndrome (MDS) | P3 | Completed | 9 | Open-label | Darbepoetin Alfa |
| NCT01099436 Neo-Adjuvant Chemotherapy (TAC) With or Without Zoledronic Acid in Treating HER2-negative Breast Cancer Patients | Breast Cancer | P3 | Completed | 250 | RCT, Open-label | cyclophosphamide, docetaxel, doxorubicin hydrochloride, zoledronic acid |
| NCT00117624 A Study of Darbepoetin Alfa for the Treatment of Anemia in Subjects With a Non-Myeloid Malignancy | Anemia | P3 | Completed | — | RCT, Double-blind | darbepoetin alfa |
| NCT02593773 Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich's Ataxia Study | Friedreich's Ataxia | P3 | Completed | 86 | Open-label | Interferon γ-1b |
| NCT00035594 Pegfilgrastim as Support to Advanced Breast Cancer Patients Receiving Chemotherapy | Neutropenia | P3 | Completed | 928 | RCT, Double-blind | pegfilgrastim |
| NCT05198934 Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation | Colorectal Cancer (CRC) | P3 | Completed | 160 | RCT, Open-label | Sotorasib, Panitumumab, Trifluridine and Tipiracil, Regorafenib |
| NCT00984815 Safety Study of HZT-501 in Patients Who Require Long-Term Daily Non-steroidal Anti-inflammatory Drug Treatment | Osteoarthritis, Rheumatoid Arthritis | P3 | Completed | 86 | Open-label | HZT-501 |
| NCT00364013 PRIME: Panitumumab Randomized Trial In Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy | Metastatic Colorectal Cancer | P3 | Completed | 1,183 | RCT, Open-label | Panitumumab, FOLFOX regimen |
| NCT05704725 A Study to Evaluate ABP 938 and Aflibercept (Eylea®) in Participants With Chorioretinal Vascular Disease (CVD) | Chorioretinal Vascular Disease | P3 | Completed | 49 | RCT, Open-label | ABP 938, Aflibercept |
| NCT03131453 A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease | Alzheimers Disease | P2P3 | Terminated | 1,145 | RCT, Double-blind | CNP520 50mg, CNP520 15mg |
| NCT00838201 Extension Study to Evaluate Long Term Safety of Denosumab in Subjects Undergoing ADT for Non-Metastatic Prostate Cancer | Cancer, Carcinoma | P3 | Completed | 384 | Open-label | Denosumab |
| NCT02263508 Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma | Melanoma | P3 | Terminated | 713 | RCT, Double-blind | Talimogene Laherparepvec, Pembrolizumab, Placebo |
| NCT03432533 A Comparison of Subject-administered Romosozumab With Healthcare Provider-administered Romosozumab for Osteoporosis | Post-Menopausal Osteoporosis | P3 | Completed | 283 | RCT, Open-label | romosozumab HCP administration with PFS |
| NCT01953328 Study of Low-Density Lipoprotein Cholesterol (LDL-C) Reduction Using Evolocumab (AMG 145) in Japanese Patients With Advanced Cardiovascular Risk | Hyperlipidemia or Mixed Dyslipidemia at High Risk for Cardiovascular Events | P3 | Completed | 409 | RCT, Double-blind | Atorvastatin, Evolocumab |
| NCT04761627 A Study to Investigate Interchangeability of ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | Psoriasis | P3 | Completed | 494 | RCT, Double-blind | Ustekinumab, ABP 654 |
| NCT01879319 Study to Assess in Home Use of Evolocumab (AMG 145) Administration Using Either an Automated Mini-doser or a Prefilled Autoinjector/Pen | Primary Hypercholesterolemia, Mixed Dyslipidemia | P3 | Completed | 164 | RCT, Open-label | Evolocumab AMD, Evolocumab AI/pen |
| NCT04851964 Efficacy and Safety of Tezepelumab in Participants With Severe Chronic Rhinosinusitis With Nasal Polyposis | Chronic Rhinosinusitis With Nasal Polyps | P3 | Completed | 416 | RCT, Double-blind | Experimental: Tezepelumab, Mometasone furoate or equivalent intranasal corticosteroid |
| NCT01270347 Trial of Aeroquin Versus Tobramycin Inhalation Solution (TIS) in Cystic Fibrosis (CF) Patients | Cystic Fibrosis | P3 | Completed | 282 | RCT, Open-label | MP-376 (Levofloxacin Solution for Inhalation), TIS (Tobramycin Inhalation Solution) |
| NCT00357903 Open-Label Extension Treatment With Etanercept (TNFR:Fc) for Participating Patients in Etanercept (TNFR:Fc) Clinical Trials | Rheumatoid Arthritis | P3 | Completed | 639 | Open-label | Etanercept |
| NCT00110955 Treatment of Anemia in Subjects With Non-Myeloid Malignancy Receiving Multicycle Chemotherapy | Anemia, Non-Myeloid Malignancies | P3 | Completed | 391 | RCT, Double-blind | Darbepoetin alfa, Placebo |
| NCT03287609 EVOlocumab for Early Reduction of LDL-cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS) | Acute Coronary Syndrome | P3 | Completed | 308 | RCT, Double-blind | Evolocumab 140 mg/mL, Placebo |
| NCT05704738 A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) | Atopic Dermatitis | P3 | Completed | 532 | RCT, Double-blind | Rocatinlimab, Placebo |
| NCT00121602 Efficacy Study: Darbepoetin Alfa for the Treatment of Anemia in Patients With Chronic Kidney Disease | Anemia, Kidney Disease | P3 | Completed | 446 | RCT, Double-blind | Darbepoetin Alfa |
| NCT00345839 E.V.O.L.V.E. Trial™: EValuation Of Cinacalcet Hydrochloride (HCl) Therapy to Lower CardioVascular Events | Secondary Hyperparathyroidism, Chronic Kidney Disease | P3 | Completed | 3,883 | RCT, Double-blind | Cinacalcet, Placebo |
| NCT00146224 Efficacy of Epoetin Alfa Deep Tank in Treatment of Anemia in Patients With Chronic Kidney Disease Receiving Hemodialysis | Nephrology | P3 | Completed | 420 | RCT, Double-blind | Epoetin alfa RB, Epoetin alfa DT |
| NCT01307423 Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA) | Psoriatic Arthritis | P3 | Completed | 529 | RCT, Double-blind | Apremilast 20mg, Apremilast 30mg, Placebo |
| NCT01854918 Open-label Extension Study of Evolocumab (AMG 145) in Adults With Hyperlipidemia and Mixed Dyslipidemia | Hyperlipidemia and Mixed Dyslipidemia | P3 | Completed | 3,681 | RCT, Open-label | Evolocumab, Standard of Care |
| NCT00110903 Treatment for Subjects With Active Rheumatoid Arthritis (RA) | Rheumatoid Arthritis | P3 | Completed | — | Open-label | Etanercept Liquid |
| NCT01194219 Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis | Plaque Psoriasis | P3 | Completed | 844 | RCT, Double-blind | Apremilast, Placebo, Topical treatments or phototherapy |
| NCT00116688 Open Label Extension Study of Romiplostim (AMG 531) in Thrombocytopenic Patients With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) | Thrombocytopenia, Idiopathic Thrombocytopenic Purpura | P3 | Completed | 313 | RCT, Open-label | Romiplostim |
| NCT05633355 A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) | Atopic Dermatitis | P3 | Completed | 187 | Open-label | Rocatinlimab |
| NCT03968978 Tezepelumab Home Use Study | Asthma | P3 | Completed | 216 | RCT, Open-label | Tezepelumab (APFS), Tezepelumab (AI) |
| NCT00339183 Comparison of Treatment Effect of Chemotherapy With Panitumumab to Chemotherapy Alone | Metastatic Colorectal Cancer | P3 | Completed | 1,186 | RCT, Open-label | Panitumumab, FOLFIRI |
| NCT00135317 AIM 3: Anemia and Iron Management With Every 3 Week Dosing in Anemic Subjects With Nonmyeloid Malignancies | Cancer | P3 | Completed | — | RCT, Open-label | darbepoetin alfa |
| NCT05899816 A Study Assessing Rocatinlimab on Vaccine Antibody Response in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET - VOYAGER) | Atopic Dermatitis, Moderate-to-severe Atopic Dermatitis | P3 | Completed | 221 | RCT, Double-blind | Rocatinlimab, Placebo |
| NCT00769704 Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma | Melanoma | P3 | Completed | 437 | RCT, Open-label | Talimogene laherparepvec, GM-CSF |
| NCT01212770 PALACE 3: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis | Psoriatic Arthritis | P3 | Completed | 505 | RCT, Double-blind | Apremilast 20mg, Apremilast 30mg, Placebo |
| NCT00111436 Evaluating the Safety of Etanercept in the Treatment of Psoriasis in Adult Subjects | Psoriasis | P3 | Completed | 912 | Open-label | Etanercept |
| NCT02125344 A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto) | Tubular Breast Cancer Stage II, Tubular Breast Cancer Stage III | P3 | Completed | 961 | RCT, Open-label | non-pegylated liposomal doxorubicin, Carboplatin, Paclitaxel, Epirubicin, Cyclophosphamide, Pertuzumab, Trastuzumab, Ferric carboxymaltose |
| NCT03701763 Efficacy and Safety Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis | Psoriasis | P3 | Completed | 245 | RCT, Double-blind | Apremilast (CC-10004) |
| NCT00109031 Palifermin for the Reduction of Oral Mucositis in Single-dose Evaluation (PROMISE) | Cancer, Lymphoma | P3 | Completed | 47 | RCT, Double-blind | palifermin, Cyclophosphamide, Etoposide, Placebo |
| NCT00508820 An Open Label Study of Romiplostim in Adult Thrombocytopenic Subjects With ITP | Idiopathic Thrombocytopenic Purpura, Thrombocytopenia | P3 | Completed | 407 | Open-label | Romiplostim |
| NCT01235442 Evaluate Efficacy, and Safety of Topical Therapy and Etanercept in Subjects With Moderate to Severe Plaque Psoriasis | Psoriasis | P3 | Completed | 592 | RCT, Single-blind | 1=Etanercept, 2=Clobetasol propionate foam |
| NCT00947297 Study of the Safety of HPN (Hyperion)-100 for the Long-Term Treatment of Urea Cycle Disorders (Treat UCD) | Urea Cycle Disorders | P3 | Completed | 60 | Open-label | HPN-100 |
| NCT02867813 Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk Open-label Extension | Dyslipidemia | P3 | Completed | 5,035 | Open-label | Evolocumab |
| NCT00119613 A Study of Subjects With Previously Untreated Extensive-Stage Small-Cell Lung Cancer (SCLC) Treated With Platinum Plus Etoposide Chemotherapy With or Without Darbepoetin Alfa | Small Cell Lung Cancer | P3 | Completed | 600 | RCT, Double-blind | placebo, darbepoetin alfa |
| NCT04607980 A Study to Investigate ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | Plaque Psoriasis | P3 | Completed | 563 | RCT, Double-blind | ABP 654, Ustekinumab |
| NCT02729025 Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition on Arterial Wall Inflammation in Patients With Elevated Lipoprotein(a) (Lp(a)) | Subjects With Hyperlipidemia, Dyslipidemia | P3 | Completed | 129 | RCT, Double-blind | Evolocumab, Placebo |
| NCT04590586 Study of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalized Patients | COVID-19 | P3 | Completed | 515 | RCT, Double-blind | Standard of care, Apremilast, Apremilast placebo, Lanadelumab, Lanadelumab placebo, Zilucoplan, Zilucoplan placebo |
| NCT00518531 Denosumab Adherence Preference Satisfaction Study | Osteoporosis | P3 | Completed | 250 | RCT, Open-label | alendronate, denosumab |
| NCT00992459 Efficacy and Safety of HPN-100 for the Treatment of Adults With Urea Cycle Disorders | Urea Cycle Disorders | P3 | Completed | 46 | RCT, Double-blind | HPN-100, Buphenyl (NaPBA) |
| NCT04338581 Evaluation of AMG 714 for Vitiligo | Vitiligo | P2 | Completed | 60 | RCT, Double-blind | AMG 714, Placebo |
| NCT07178912 Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromosome (ph)-Positive and/or BCR::ABL1 Positive Acute Lymphoblastic Leukemia (ALL) | Phase II Clinical Trial, Blinatumomab | P2 | Not Yet Recruiting | 60 | Open-label | Blinatumomab, olverembatinib |
| NCT00193479 Combination Chemotherapy and Rituximab With Pegfilgrastim Followed by Rituximab, in Large B-Cell Non-Hodgkin's Lymphoma | Non-Hodgkins Lymphoma | P2 | Completed | 51 | Open-label | Cyclophosphamide, Mitoxantrone, Vincristine, Prednisone, Rituximab |
| NCT00940316 Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer | Colorectal Cancer | P2 | Completed | 28 | RCT, Open-label | panitumumab, erlotinib hydrochloride, irinotecan hydrochloride |
| NCT00400764 A Study of Dulanermin in Combination With Rituximab in Subjects With Follicular and Other Low Grade, CD20+, Non-Hodgkin's Lymphomas | Non-Hodgkin's Lymphoma | P1P2 | Terminated | 72 | RCT, Open-label | Dulanermin, Rituximab |
| NCT00632541 A Phase II Study of Bevacizumab + Sorafenib in Metastatic Breast Cancer | Metastatic Breast Cancer | P2 | Terminated | 18 | Open-label | Sorafenib, Bevacizumab |
| NCT05054725 Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies | Non-Small Cell Lung Cancer | P2 | Completed | 47 | Open-label | RMC-4630, Sotorasib |
| NCT04448834 Blincyto Amgen Acrotech BioPharma PH2 Blincyto Marqibo R/R Philadelphi CD19+ ALL | B-cell Acute Lymphoblastic Leukemia | P2 | Withdrawn | — | Open-label | Blinatumomab |
| NCT03301467 Controlled Trial Evaluating Avacopan in C3 Glomerulopathy | C3 Glomerulopathy (C3G) | P2 | Completed | 57 | RCT, Double-blind | Avacopan, Avacopan Matching Placebo |
| NCT04169347 FOLFOXIRI Plus Panitumumab in Metastatic RAS Wild-type, Left-sided Colorectal Cancer | Colorectal Cancer Metastatic | P2 | Unknown | 27 | Open-label | Oxaliplatin |
| NCT00346099 Study of Panitumumab Given First With Capecitabine and Oxaliplatin (CAPOX) and Then With Capecitabine and Radiation of the Pelvis for Treatment of Patients With Rectal Cancers That May or May Not Have Spread Beyond the Rectum | Rectal Cancer, Neoplasm Metastasis | P2 | Withdrawn | — | Open-label | Panitumumab with capecitabine and oxaliplatin (CAPOX) followed by, Panitumumab with capecitabine and radiation |
| NCT00591851 Phase II Study of Dose-Dense Doxurubicin and Cyclophosphamide (AC) Followed By Paclitaxel With Trastuzumab in HER2/ NEU-Amplified Breast Cancer: Feasibility | Breast Cancer | P2 | Completed | 70 | Open-label | AC [Adriamycin (A) (also known as doxorubicin) and Cyclophosphamide (C)] Followed By Paclitaxel (P) |
| NCT01464034 A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma | Multiple Myeloma | P1P2 | Terminated | 136 | Open-label | Carfilzomib, Pomalidomide, Dexamethasone |
| NCT06068153 AMG510 (sotorasib) Plus Lenvatinib As Second-line Treatment in Patients with KRASG12C Mutant, Metastatic NSCLC | Metastatic Non Small Cell Lung Cancer, KRAS G12C | P2 | Withdrawn | — | Open-label | Sotorasib, Lenvatinib |
| NCT00293202 Safety and Efficacy Study of the Effect of Etanercept in Hemodialysis Patients | End Stage Renal Disease | P2 | Terminated | 10 | RCT, Double-blind | Etanercept, Placebo |
| NCT00508625 A Study of AMG 951 [rhApo2L/TRAIL] in Subjects With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) Treated With Chemotherapy +/- Bevacizumab | Non-Small Cell Lung Cancer | P2 | Completed | 213 | RCT, Open-label | AMG 951 (rhApo2L/TRAIL), Bevacizumab, Carboplatin, Paclitaxel |
| NCT05180422 A Phase I/II Study of AMG 510 in Combination With MVASI in Patients With Advanced, Unresectable or Metastatic KRAS G12C Mutant NSCLC With Asymptomatic Brain Metastasis | Non Small Cell Lung Cancer | P1P2 | Withdrawn | — | Open-label | AMG 510, MVASI |
| NCT00585650 Study of Tumor Necrosis Factor Receptor Fusion Protein Etanercept (Enbrel) in Psoriasis of the Hands and/or Feet | Psoriasis | P1P2 | Completed | 20 | RCT, Double-blind | Etanercept |
| NCT03815279 A Nationwide Phase 2 Trial of Patients With Smoldering and Active Multiple Myeloma (MM) | Multiple Myeloma, Smoldering Multiple Myeloma | P2 | By Invite | 80 | Open-label | Carfilzomib, Lenalidomide, Dexamethasone |
| NCT03931642 BLINAtumomab After R-CHOP Debulking Therapy for Patients With Richter Transformation | Richter Syndrome | P2 | Completed | 41 | Open-label | RCHOP, Blinatumomab |
| NCT00050674 Docetaxel and Gemcitabine With Filgrastim-SD/01 Support in Patients With Advanced Non-Small Cell Lung Carcinoma | Non-small Cell Lung Cancer | P2 | Completed | 40 | Open-label | Filgrastim-SD/01 |
| NCT04631601 Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC) | Metastatic Castration-resistant Prostate Cancer | P1P2 | Terminated | 55 | RCT, Open-label | Acapatamab, Enzalutamide, Abiraterone, AMG 404 |
| NCT02174861 A Study to Assess the Long-term Safety and Efficacy of Erenumab (AMG 334) in Chronic Migraine Prevention. | Treatment for Prevention of Chronic Migraine | P2 | Completed | 609 | Open-label | Erenumab |
| NCT00613730 Adenocarcinoma of the Pancreas Treated With Panitumumab and Gemcitabine Regimen to Investigate Overall Survival as Primary Endpoint | Cancer of Pancreas, Cancer of the Pancreas | P2 | Terminated | 3 | Open-label | Gemcitabine, panitumumab |
| NCT02128230 UARK 2012-02 Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete Remission | Multiple Myeloma | P2 | Terminated | 20 | Open-label | Induction 1 - MEL-10+CFZ-TD-PACE, First Transplant - MEL-80+CFZ-TD-PACE + PBSC (biologic), Inter-Therapy - MEL-20+CFZ-TD-PACE (75%), Second Transplant - MEL-80+CFZ-TD-PACE + PBSC (biologic), Consolidation - CFZ-TD-PACE, Maintenance - CFZ-R(T)-D |
| NCT02630459 A Safety and Efficacy Study to Evaluate AMG 334 in Migraine Prevention | Migraine | P2 | Completed | 475 | RCT, Double-blind | Placebo, Erenumab, Erenumab |
| NCT01832727 Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma | Multiple Myeloma | P1P2 | Terminated | 65 | Open-label | Oprozomib, Dexamethasone |
| NCT01126112 Study of First-line Single-agent Panitumumab in Frail Elderly Patients With Advanced Wild Type K-RAS Colorectal Cancer | Colorectal Cancer | P2 | Completed | 33 | Open-label | Panitumumab |
| NCT01690143 Carfilzomib + High Dose Melphalan as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation | Multiple Myeloma | P1P2 | Completed | 45 | Open-label | Carfilzomib, Melphalan |
| NCT00104650 Study of AMG 162 in Subjects With Advanced Cancer Currently Being Treated With Intravenous (IV) Bisphosphonates | Bone Metastases in Men With Hormone-Refractory Prostate Cancer, Bone Metastases in Subjects With Advanced Breast Cancer | P2 | Completed | 111 | RCT, Open-label | IV Bisphosphonate q 4 weeks |
| NCT01916109 Study of Gemcitabine, Carboplatin, and Panitumumab (GCaP) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer | Bladder Cancer | P2 | Terminated | 4 | Open-label | Gemcitabine, Carboplatin, Panitumumab |
| NCT00947544 Study of the Safety and Tolerability of HPN-100 Compared to Sodium Phenylbutyrate in Children With Urea Cycle Disorders | Urea Cycle Disorders | P2 | Completed | 17 | Open-label | HPN-100, NaPBA |
| NCT00095264 A Study of Darbepoetin Alfa in Anemic Subjects With Low Risk Myelodysplastic Syndrome | Myelodysplastic Syndromes | P2 | Completed | 209 | Open-label | Darbepoetin Alfa |
| NCT03982992 Allogeneic Donor Lymphocyte Infusions Combined With Blinatumomab | B Cell Precursor Acute Lymphoblastic Leukemia With Mixed Chimerism or Minimal Residual Disease After Allogeneic Stem Cell Transplantation, B-Cell Acute Lymphoblastic Leukemia | P2 | Withdrawn | — | Open-label | Blinatumomab in combination with donor lymphocyte infusion |
| NCT03160079 Blinatumomab & Pembrolizumab for Adults With Relapsed/Refractory B-cell ALL With High Marrow Lymphoblasts | B-Cell Acute Lymphoblastic Leukemia, Adult | P1P2 | Completed | 16 | Open-label | blinatumomab, pembrolizumab |
| NCT02052882 Study of Romiplostim for Chemotherapy Induced Thrombocytopenia | Isolated Chemotherapy-induced Thrombocytopenia | P2 | Completed | 60 | Open-label | romiplostim |
| NCT00756444 A Randomized Phase 2 Pharmacokinetic Trial of Chemotherapy With or Without Panitumumab in Patients With Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck | Squamous Cell Carcinoma of Head and Neck | P2 | Completed | 67 | RCT, Open-label | Panitumumab, Cisplatin, 5FU |
| NCT01712009 NOLAN: Naproxen or Loratadine and Neulasta | Bone Pain in Stage I - III Breast Cancer | P2 | Completed | 600 | RCT, Open-label | Naproxen, Loratadine, Pegfilgrastim, Chemotherapy |
| NCT03809663 A Dose Ranging Placebo-Controlled Double-Blind Study to Evaluate the Safety and Efficacy of Tezepelumab in Atopic Dermatitis | Atopic Dermatitis | P2 | Terminated | 251 | RCT, Double-blind | Tezepelumab |
| NCT00194753 Adjuvant Therapy for High-Risk Breast Cancer With Wkly Adriamycin & Oral Cytoxan With G-CSF for 12 Wks; Wkly Taxol x 12 | Breast Neoplasm | P2 | Completed | 80 | Open-label | Paclitaxel, Doxorubicin, Cyclophosphamide, G-CSF |
| NCT00072319 Neoadjuvant or Adjuvant Epirubicin, Cyclophosphamide, and Paclitaxel in Treating Women With Stage I, Stage II, or Stage III Breast Cancer | Breast Cancer | P2 | Completed | — | — | filgrastim, cyclophosphamide, epirubicin hydrochloride, paclitaxel |
| NCT00540657 A Phase II Study of CCX282-B in Patients With Celiac Disease | Celiac Disease | P2 | Completed | 90 | RCT, Double-blind | CCX282-B, Placebo |
| NCT02334306 A Phase 2a, Randomized, Placebo Controlled, Study to Evaluate the Safety and Efficacy of AMG 557/MEDI5872 in Primary Sjögren's Syndrome | Primary Sjögren's Syndrome | P2 | Completed | 32 | RCT, Double-blind | AMG 557/MEDI5872 |
| NCT02682693 Denosumab as an add-on Neoadjuvant Treatment (GeparX) | Breast Cancer Female NOS, Tubular Breast Cancer Stage II | P2 | Completed | 780 | RCT, Open-label | Denosumab, nab-Paclitaxel, Epirubicin, Cyclophosphamide, Carboplatin, Trastuzumab, Pertuzumab |
| NCT00094809 Chemotherapy Administered Every 2 Weeks With or Without Pegfilgrastim in Subjects With Advanced or Metastatic Colon Cancer | Colon Cancer, Colorectal Cancer | P2 | Completed | 252 | RCT, Double-blind | Placebo, Pegfilgrastim |
| NCT01308840 Gemcitabine, Oxaliplatin and Panitumumab in Kras/B-raf Wild-Type Biliary Track and Gallbladder Cancer | Biliary Tract Cancer, Gallbladder Cancer | P2 | Completed | 31 | Open-label | Panitumumab, oxaliplatin, gemcitabine |
| NCT00583674 Phase 2 Study of AMG 386 (20060439) in Combination With Cisplatin & Capecitabine in Subjects With Metastatic Gastric, Gastroesophageal Junction, or Distal Esophageal Adenocarcinoma | Gastrointestinal Cancer | P2 | Completed | 171 | RCT, Double-blind | AMG 386 placebo, AMG 386 10mg/kg, AMG 386 3mg/kg, Cisplatin, Capecitabine, Cisplatin, Capecitabine, Cisplatin, Capecitabine |
| NCT00306215 A Study to Evaluate the Efficacy and Safety of CCX282-B in Subjects With Moderate to Severe Crohn's Disease | Crohn's Disease | P2 | Completed | 436 | RCT, Double-blind | CCX282-B |
| NCT00531284 Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma | Ovarian Cancer, Renal Cancer | P1P2 | Completed | 184 | Open-label | Carfilzomib, Dexamethasone |
| NCT03792763 Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients | Multiple Myeloma | P2 | Completed | 8 | RCT, Double-blind | Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA], Placebo 1.7 ml Subcutaneous Solution |
| NCT00306189 A Randomized, Double-blind, Placebo-controlled, Dose Response Study of AMG 162 (Denosumab) in Japanese Postmenopausal Osteoporotic Subjects | Osteoporosis | P2 | Completed | 212 | RCT, Double-blind | 100 mg AMG 162, 60 mg AMG 162, 14 mg AMG 162, Placebo |
| NCT01989689 Etanercept and Vascular Function in Psoriasis | PSORIASIS | P2 | Completed | 24 | RCT, Double-blind | Etanercept, Placebo |
| NCT00418938 SPIRITT - Second-Line Panitumumab Irinotecan Treatment Trial | Cancer, Colon Cancer | P2 | Completed | 266 | RCT, Open-label | Panitumumab, Bevacizumab, Leucovorin, Irinotecan, 5-Fluorouracil |
| NCT00113789 Evaluating Pegfilgrastim and a Multi-Day Topotecan Regimen in Subjects With Relapsed or Refractory Ovarian Cancer | Ovarian Cancer | P2 | Completed | 21 | RCT, Double-blind | — |
| NCT01285310 Study of Apremilast to Evaluate the Safety and Effectiveness for Patients With Rheumatoid Arthritis | Rheumatoid Arthritis | P2 | Terminated | 237 | RCT, Double-blind | Apremilast 30 mg, Apremilast 20 mg, Placebo |
| NCT00425204 Study for Patients Who Have Benefited and Tolerated Prior Panitumumab Treatment | Colorectal Cancer, Non-Small Cell Lung Cancer | P2 | Completed | 31 | Open-label | Panitumumab (ABX-EGF) |
| NCT03703908 A Study of CCX140-B in Subjects With Primary FSGS and Nephrotic Syndrome | Focal Segmental Glomerulosclerosis | P2 | Terminated | 5 | Open-label | CCX140-B |
| NCT05368103 Study of DAXDILIMAB for the Treatment of Moderate-to-Severe Alopecia Areata | Alopecia Areata | P2 | Completed | 30 | Open-label | Daxdilimab |
| NCT00614523 Romiplostim Treatment of Thrombocytopenia in Subjects With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) | MDS, Myelodysplastic Syndromes | P2 | Completed | 250 | RCT, Double-blind | Placebo, Romiplostim |
| NCT00094861 Study to Evaluate Palifermin in the Reduction of Dysphagia in Patients With Locally Advanced Non-Small Cell Lung Cancer (NSCLC) | Dysphagia, Non-Small Cell Lung Cancer | P2 | Completed | 100 | RCT, Double-blind | Palifermin, Placebo, Paclitaxel, Carboplatin |
| NCT04287855 Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone With Carfilzomib in Relapsed or Refractory Multiple Myeloma | Multiple Myeloma in Relapse, Multiple Myeloma, Refractory | P2 | Unknown | 82 | Open-label | Isatuximab, Carfilzomib, Pomalidomide, Dexamethasone |
| NCT01907308 Trebananib (AMG 386) in Combination With Docetaxel for Advanced Urothelial Carcinoma | Urothelial Carcinoma | P2 | Withdrawn | — | Open-label | AMG 386, Docetaxel |
| NCT02802163 Induction Therapy for Multiple Myeloma With Carfilzomib, Lenalidomide,Dexamethasone,Panobinostat | Multiple Myeloma | P1P2 | Withdrawn | — | Open-label | Panobinostat, Carfilzomib, Lenalidomide, Dexamethasone |
| NCT00530816 Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma | Multiple Myeloma | P2 | Completed | 164 | Open-label | carfilzomib |
| NCT01677858 A Study of Weekly Carfilzomib in Combination With Dexamethasone for Progressive Multiple Myeloma | Multiple Myeloma | P1P2 | Completed | 116 | Open-label | Carfilzomib, Dexamethasone |
| NCT04427306 Neoadjuvant T-VEC in High Risk Early Melanoma | Melanoma | P2 | SUSPENDED | 6 | Open-label | T-Vec |
| NCT01143038 Interventional Study in Adults With Immune Thrombocytopenia Purpura (ITP) Receiving Romiplostim | Idiopathic Thrombocytopenic Purpura | P2 | Completed | 75 | Open-label | Romiplostim |
| NCT04956809 Effect of Dapagliflozin on Submaximal Exercise Tolerance in Heart Failure | HFrEF | P2 | Completed | 3 | RCT, Double-blind | Dapagliflozin 10Mg Tab, Placebo |
| NCT00936650 A Study to Assess the Efficacy and Safety of Twice-Daily Dose Regimens of an Oral Calcimimetic Agent AMG 073 (Cinacalcet) in Primary Hyperparathyroidism (PHPT) | Hyperparathyroidism, Primary | P2 | Completed | 78 | RCT, Double-blind | placebo, cinacalcet |
| NCT00819780 PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors | Colon Cancer, Colorectal Cancer | P2 | Completed | 285 | RCT, Open-label | Panitumumab, Bevacizumab, mFOLFOX6 |
| NCT01471782 Clinical Study With Blinatumomab in Pediatric and Adolescent Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia | Acute Lymphoblastic Leukemia | P1P2 | Completed | 93 | Open-label | Blinatumomab |
| NCT00866359 A Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in the Treatment of Behçet Disease | Behcet Syndrome | P2 | Completed | 111 | RCT, Double-blind | Apremilast (CC-10004), Placebo |
| NCT04057937 A Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Japanese Subjects With Palmoplantar Pustulosis | Palmoplantaris Pustulosis | P2 | Completed | 90 | RCT, Double-blind | Apremilast, Placebo |
| NCT02969837 Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma | Multiple Myeloma | P2 | Completed | 46 | Open-label | Elotuzumab, Carfilzomib, Lenalidomide, Dexamethasone |
| NCT02366195 Single-arm Trial to Evaluate the Role of the Immune Response to Talimogene Laherparepvec in Unresected Melanoma | Unresected Stage IIIb to IVM1c Melanoma | P2 | Completed | 112 | Open-label | Talimogene Laherparepvec |
| NCT01144195 A Clinical Trial of Panitumumab in Combination With FOLFIRI Chemotherapy as Second Line Treatment in Subjects With Metastatic Colorectal Cancer Expressing Wild-type KRAS and Who Had Progressed ≥ 6 Months After the Last Dose of the First Line Chemotherapy | Metastatic Colorectal Cancer | P2 | Unknown | 80 | Open-label | Panitumumab + FOLFIRI |
| NCT00035607 Chemotherapy Related Anemia | Anemia, Non-Myeloid Malignancies | P2 | Completed | 120 | RCT, Open-label | Darbepoetin alfa SC, Darbepoetin alfa IV |
| NCT00422019 A Phase II Study to Treat Subjects With Advanced Renal Cell Carcinoma | Advanced Renal Cell Carcinoma | P2 | Completed | 61 | Open-label | AMG 102 at 10 mg/kg, AMG 102 at 20 mg/kg |
| NCT00771030 Study to Evaluate the Safety, PK, PD and Efficacy of AMG 827 in Adults With Rheumatoid Arthritis | Rheumatoid Arthritis | P1P2 | Completed | 40 | RCT, Double-blind | Brodalumab |
| NCT01775553 Study of High Dose Carfilzomib in Multiple Myeloma Patients Who Have Progressed On Standard Dose Carfilzomib | Relapse Multiple Myeloma, Refractory Multiple Myeloma | P2 | Completed | 13 | Open-label | Carfilzomib |
| NCT00752570 A Phase 2, Randomized, Double Blind, Placebo Controlled Study of AMG 386 in Combination With FOLFIRI in Subjects With Previously Treated Metastatic Colorectal Carcinoma | Cancer, Carcinoma | P2 | Completed | 144 | RCT, Double-blind | AMG 386, AMG 386 Placebo, FOLFIRI |
| NCT00041470 Navelbine, Taxol, Herceptin and Neupogen in Stage IV Breast Cancer: A Phase I - II Trial | Breast Cancer | P1P2 | Terminated | 38 | Open-label | Paclitaxel, Vinorelbine, Herceptin, Filgrastim |
| NCT01440257 A Study to Evaluate the Effect of CCX140-B on Urinary Albumin Excretion in Subjects With Type 2 Diabetes and Albuminuria | Diabetic Nephropathy, Type 2 Diabetes Mellitus | P2 | Completed | 20 | RCT, Double-blind | Placebo, CCX140-B |
| NCT03584711 FOLFOX + Panitumumab According to a "Stop and go" Strategy With a Reintroduction Loop After Progression on Fluoropyrimidine as Maintenance Treatment, as the First Line in Patients With Metastatic Colorectal Adenocarcinoma Without a RAS Mutation | Metastatic Colorectal Cancer | P2 | Completed | 118 | Open-label | — |
| NCT00475293 Panitumumab in Combination With Irinotecan Chemotherapy as 2nd-line Therapy in Subjects With mCRC | Metastatic Colorectal Cancer | P2 | Completed | 85 | Open-label | Panitumumab and CPT-11 |
| NCT01233687 AMG 102 and Erlotinib for Advanced Non-Small Cell Lung Cancer | Carcinoma, Non-Small-Cell Lung | P1P2 | Completed | 49 | Open-label | AMG 102 and erlotinib |
| NCT00035620 Pegfilgrastim as Support to Pediatric Sarcoma Patients Receiving Chemotherapy | Sarcoma, Neutropenia | P2 | Completed | 44 | RCT, Open-label | pegfilgrastim, filgrastim |
| NCT03974360 Efficacy and Tolerability of Erenumab in the Prophylactic Treatment of Persistent Post-Traumatic Headache | Post-Traumatic Headache, Mild Traumatic Brain Injury | P2 | Completed | 100 | Open-label | AMG 334 |
| NCT00110929 Treatment for Patients With Secondary Hyperparathyroidism of End-Stage Renal Disease (ESRD) | End Stage Renal Disease | P2 | Completed | 850 | RCT, Open-label | AMG 073 |
| NCT00111462 Evaluating Treatment of Anemia in Subjects With Non-Myeloid MalignanciesReceiving Multicycle Chemotherapy | Anemia, Non-Myeloid Malignancies | P2 | Completed | — | RCT, Open-label | Darbepoetin alfa |
| NCT00511459 Phase 2 Study of AMG 386 Plus Paclitaxel With or Without Bevacizumab as First Line Therapy in Her2-Negative Breast Cancer Patients | Locally Recurrent and Metastatic Breast Cancer | P2 | Completed | 228 | RCT, Double-blind | AMG 386 Placebo, AMG 386, Bevacizumab, AMG 386, AMG 386, Paclitaxel |
| NCT04231682 A Study to Evaluate Efficacy and Safety of Denosumab for Prevention and Treatment of Osteoporosis in 1st Time Liver Transplant Recipients. | Osteoporosis | P2 | Withdrawn | — | RCT, Double-blind | Denosumab Injection, Placebos |
| NCT00189488 Trial to Evaluate Palifermin in the Reduction of Acute Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Allogeneic Marrow/Peripheral Blood Progenitor Cell (PBPC) Transplantation | Graft Versus Host Disease, Hematologic Malignancies | P2 | Completed | 155 | RCT, Double-blind | Palifermin, Placebo, Methotrexate |
| NCT02597062 High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma | Multiple Myeloma | P2 | Completed | 76 | Open-label | Carfilzomib, Cyclophosphamide, Dexamethasone |
| NCT01150890 Brodalumab (AMG 827) in Adults With Moderate to Severe Crohn's Disease | Crohn's Disease | P2 | Terminated | 130 | RCT, Double-blind | Brodalumab, Placebo |
| NCT01952574 Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention | Migraine | P2 | Completed | 483 | RCT, Double-blind | Erenumab, Placebo, Erenumab PFS, Erenumab AI/Pen |
| NCT00925821 Lenalidomide-Adriamycin-Dexamethasone (RAD) Induction Followed by Stem Cell Transplant in Newly Diagnosed Multiple Myeloma | Multiple Myeloma | P2 | Completed | 146 | Open-label | RAD |
| NCT01199289 A Study to Evaluate the Dosing of AMG 827 for Subjects With Inadequately Controlled Asthma | Asthma | P2 | Completed | 315 | RCT, Double-blind | AMG 827, Placebo |
| NCT00885885 Safety and Efficacy Study of FOLFOX4+Panitumumab vs.FOLFIRI+Panitumumab in Subjects WT KRAS Colorectal Cancer and Liver-only Metastases | Colorectal Cancer | P2 | Completed | 80 | RCT, Open-label | Panitumumab+FOLFOX-4, Panitumumab+FOLFIRI |
| NCT00111423 Evaluating the Safety of Extended Treatment With Pegsunercept (PEG sTNF-RI)in Subjects With Rheumatoid Arthritis (RA) | Rheumatoid Arthritis | P2 | Completed | 216 | RCT, Double-blind | Pegsunercept (PEG sTNF-RI) |
| NCT00446446 PRISM (Panitumumab Regimen In Second-line Monotherapy of Head and Neck Cancer) | Cancer, Carcinoma | P2 | Completed | 52 | Open-label | Panitumumab |
| NCT00639717 Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Transplant | Graft Versus Host Disease | P2 | Completed | 48 | Open-label | tacrolimus (standard GVHD prophylaxis), mycophenolate (standard GVHD prophylaxis), etanercept, methoxsalen |
| NCT03795558 A Study to Investigate the Influence of PTH-lowering by Etelcalcetide (Parsabiv®) on the Calcification Propensity of Serum in Dialysis Patients | End Stage Renal Disease | P2 | Completed | 37 | Open-label | Etelcalcetide |
| NCT00002126 A Randomized, Controlled, Multicenter Trial of Filgrastim (Recombinant-Methionyl Human Granulocyte Colony Stimulating Factor; G-CSF) for the Prevention of Grade 4 Neutropenia in Patients With HIV Infection. | HIV Infections, Cytopenias | P2 | Completed | 250 | — | Filgrastim |
| NCT03839459 Denosumab for Smoldering Multiple Myeloma | Smoldering Multiple Myeloma | P2 | Completed | 20 | Open-label | Denosumab |
| NCT04270760 Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction - DOSE Finding Study | Cardiovascular Disease | P2 | Completed | 281 | RCT, Double-blind | Olpasiran, Placebo |
| NCT02575833 Treadmill Cardiovascular Safety Study of Erenumab (AMG 334) | Stable Angina | P2 | Completed | 89 | RCT, Double-blind | Erenumab, Placebo |
| NCT02613416 Denosumab and MRI Breast Imaging | Breast Cancer | P2 | Completed | 42 | Open-label | Denosumab |
| NCT00140244 Randomized, Placebo-Controlled Study of Leptin for the Treatment of HIV Lipodystrophy and Metabolic Syndrome | HAART-induced Lipodystrophy and Metabolic Syndrome | P2 | Completed | 7 | RCT, Double-blind | r-metHuLeptin, Placebo |
| NCT00773734 Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate-to-Severe Plaque-Type Psoriasis (Core Study) | Psoriasis, Plaque-type Psoriasis | P2 | Completed | 352 | RCT, Double-blind | Apremilast 10mg, Apremilast 20mg, Apremilast 30 mg, Placebo, Apremilast 30mg, Apremilast 20mg |
| NCT01305772 Identification of Gene Expression Signature for Panitumumab Sensitivity in Untreated Locally Advanced SCCHN | Squamous Cell Carcinoma of the Head and Neck | P2 | Terminated | 6 | Open-label | Panitumumab |
| NCT05669599 Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus | Obesity, Overweight | P2 | Completed | 592 | RCT, Double-blind | Maridebart Cafraglutide, Placebo |
| NCT02215200 ATG-GCSF in New Onset Type 1 Diabetes | Diabetes Mellitus, Type 1 | P2 | Completed | 89 | RCT, Double-blind | Anti-Thymocyte Globulin (ATG), Granulocyte colony stimulating factor (GCSF), Placebo (for ATG), Placebo (for GCSF) |
| NCT02429882 Study of Efficacy and Safety of Brodalumab Compared With Placebo in Subjects With Axial Spondyloarthritis | Axial Spondyloarthritis | P2 | Withdrawn | — | RCT, Double-blind | Brodalumab 210 mg, Placebo |
| NCT00682383 Combined Modality Therapy With Growth Factor Support in Locally Advanced Non-small Cell Lung Cancer (NSCLC) | Unresectable Locally Advanced NSCLC | P2 | Completed | 26 | Open-label | Cisplatin; Etoposide; Radiation therapy; Docetaxel; Neulasta |
| NCT04787341 PAnitumumab REchallenge Followed by REgorafenib Versus the Reverse Sequence | Colorectal Cancer | P2 | Completed | 213 | RCT, Open-label | Regorafenib, Panitumumab |
| NCT01988103 Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) In Japanese Patients With Moderate-To-Severe Plaque-Type Psoriasis | Psoriasis, Psoriatic Arthritis | P2 | Completed | 254 | RCT, Double-blind | Apremilast, Apremilast, Placebo |
| NCT02000427 Blinatumomab in Adults With Relapsed/Refractory Philadelphia Positive B-precursor Acute Lymphoblastic Leukemia | Relapsed/Refractory Philadelphia Positive B-precursor ALL | P2 | Completed | 45 | Open-label | Blinatumomab |
| NCT03656666 The AP-GELP Study: A Clinical Trial on the Effects of Apremilast in Female Genital Erosive Lichen Planus | Lichen Planus of Vulva, Female Genital Disease | P2 | Unknown | 42 | RCT, Double-blind | Apremilast, Placebo |
| NCT00043186 Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density | Low Bone Mineral Density | P2 | Completed | 412 | RCT, Double-blind | Placebo, Denosumab, Alendronate |
| NCT03161756 Evaluation of Denosumab in Combination With Immune Checkpoint Inhibitors in Patients With Unresectable or Metastatic Melanoma | Melanoma Stage Iv, Melanoma Stage Iii | P1P2 | Unknown | 72 | Open-label | Denosumab, Nivolumab, Ipilimumab |
| NCT01384994 Panitumumab After Resection of Liver Metastases From Colorectal Cancer in KRAS Wild-type Patients | Colorectal Cancer, KRAS Wildtype | P2 | Unknown | 111 | RCT, Open-label | Folic Acid, 5-FU, 5-FU, Oxaliplatin, Panitumumab, Panitumumab, Folic Acid, 5-FU, 5-FU, Oxaliplatin |
| NCT02983097 Therapy of Non-Hodgkin-Lymphoma by Combination of Lenalidomide + Rituximab, Dexa, High-dose ARA-C and CisP | Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma Grade III (FL III°) | P1P2 | Terminated | 34 | Open-label | Rituximab, Cisplatin, Carboplatin, Dexamethasone, Cytarabine, Lenalidomide, PegFilgrastim |
| NCT00117897 Treatment for Subjects With Non-Hodgkin's Lymphoma | Non-Hodgkin's Lymphoma | P2 | Completed | — | RCT, Open-label | pegfilgrastim, Filgrastim |
| NCT00808639 Dose-Dense MVAC With Pegfilgrastim Support in Subjects With Muscle-Invasive Urothelial Carcinoma | Bladder Cancer, Muscle-invasive Bladder Cancer | P2 | Completed | 39 | Open-label | Methotrexate, Doxorubicin, vinblastine, cisplatin, Pegfilgrastim |
| NCT02222155 Clinical Trial to Evaluate Safety and Efficacy of CCX168 in ANCA-Associated Vasculitis | ANCA-associated Vasculitis | P2 | Completed | 42 | RCT, Double-blind | CCX168 10 mg, twice daily, plus cyclophosphamide/rituximab plus glucocorticoids, CCX168 30 mg, twice daily, cyclophosphamide/rituximab plus glucocorticoids |
| NCT01059448 Safety and Efficacy of AMG 827 in Subjects With RA | Rheumatoid Arthritis | P2 | Terminated | 211 | Open-label | AMG 827 |
| NCT01479179 Trastuzumab in Combination With AMG 479 in HER-2 Overexpressing MBC Progressing on Trastuzumab | Breast Cancer | P1P2 | Withdrawn | — | Open-label | AMG 479, Trastuzumab |
| NCT00527085 12-month Study of AMG 073 in Renal Osteodystrophy | Renal Osteodystrophy | P2 | Completed | 45 | RCT, Double-blind | AMG 073, Placebo |
| NCT00887965 A Transiliac Crest Bone Histology and Histomorphometry Study in Postmenopausal Women With Low Bone Mass or Osteoporosis Previously Treated With Denosumab | Low Bone Mass, Low Bone Mineral Density | P2 | Completed | 15 | Open-label | Previous denosumab |
| NCT02096666 A Phase 1/2 Study Evaluating AMG 337 in Asian Subjects | Stomach Neoplasms | P1P2 | Completed | 11 | Open-label | AMG 337 |
| NCT01741792 Clinical Study With Blinatumomab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) | Diffuse Large B-cell Lymphoma | P2 | Completed | 25 | Open-label | Blinatumomab |
| NCT00597909 Efficacy and Safety Study of Ammonul® in Patients With Grade 3 or 4 Hepatic Encephalopathy | Hepatic Encephalopathy | P2 | Terminated | 1 | RCT, Double-blind | sodium phenylacetate and sodium benzoate injection 10% / 10%, sodium phenylacetate and sodium benzoate injection 10% / 10%, placebo solution (10% dextrose) |
| NCT00540696 Study to Develop a Screening Tool for Functional Capacity in Anemic Subjects With Nonmyeloid Malignancies Receiving Chemotherapy and Darbepoetin Alfa | Anemia, Non-Myeloid Malignancies | P2 | Completed | 300 | RCT, Open-label | darbepoetin alfa |
| NCT01207388 Confirmatory Phase II Study of Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL) | B-cell Acute Lymphoblastic Leukemia | P2 | Completed | 116 | Open-label | Blinatumomab |
| NCT00110942 Treatment for Patients With Osteoarthritis (OA) | Osteoarthritis | P2 | Completed | 160 | RCT, Double-blind | Systemic AMG 108 |
| NCT07061080 Refractory Advanced diGestive Neuroendocrine Carcinomas Treated With tARlatamab | Advanced Neuroendocrine Carcinomas of The Digestive System, Advanced Neuroendocrine Carcinomas Unknown Primary Origin | P2 | Terminated | 1 | RCT, Open-label | Tarlatamab, standard of care second-line chemotherapy (FOLFIRI) |
| NCT03422627 Safety and Efficacy of Efavaleukin Alfa in Subjects With Steroid Refractory Chronic Graft Versus Host Disease | Chronic Graft Versus Host Disease cGVHD | P1P2 | Terminated | 32 | Open-label | Efavaleukin Alfa |
| NCT06376045 A Phase 2, Dose Ranging Study Assessing Rocatinlimab in Moderate-to-severe Asthma | Asthma | P2 | Terminated | 317 | RCT, Double-blind | Rocatinlimab, Placebo |
| NCT01365559 Study of Carfilzomib for Multiple Myeloma Patients Who Are Relapsed/Refractory to Bortezomib-containing Treatments | Multiple Myeloma | P1P2 | Completed | 39 | Open-label | Group A: Carfilzomib & Non-IMiD Regimen, Group B: Carfilzomib & IMiD containing regimen. |
| NCT02014441 Single-arm Trial to Evaluate the Biodistribution and Shedding of Talimogene Laherparepvec | Melanoma | P2 | Completed | 61 | Open-label | Talimogene laherparepvec |
| NCT02047253 Phase 2 Trial of Carfilzomib for Metastatic Castration-resistant Prostate Cancer Following Treatment | Metastatic Castration-resistant Prostate Cancer | P2 | Completed | 28 | Open-label | Carfilzomib, Dexamethasone, Acyclovir |
| NCT03536754 A Study of CCX140-B in Subjects With FSGS | FSGS, Focal Segmental Glomerulosclerosis | P2 | Completed | 46 | RCT, Double-blind | CCX140-B, CCX140-B, CCX140-B |
| NCT05591222 Study of Daxdilimab (HZN-7734) in Participants With Moderate-to-Severe Primary Discoid Lupus Erythematosus | Discoid Lupus Erythematosus | P2 | Terminated | 72 | RCT, Double-blind | Placebo, Daxdilimab |
| NCT03141203 Evaluation of the Combination of Romidepsin and Carfilzomib in Relapsed/Refractory Peripheral T Cell Lymphoma Patients | Peripheral T Cell Lymphoma | P1P2 | Completed | 50 | Open-label | Romidepsin, Carfilzomib |
| NCT03600883 A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100) | KRAS p.G12C Mutant Advanced Solid Tumors | P1P2 | Completed | 713 | RCT, Open-label | sotorasib, Anti PD-1/L1, Midazolam |
| NCT00936988 A Multicenter, Open-label Extension Study to Assess the Long-term Safety and Efficacy of an Oral Calcimimetic Agent AMG 073 (Cinacalcet) in Primary Hyperparathyroidism | Hyperparathyroidism, Primary | P2 | Completed | 45 | Open-label | cinacalcet |
| NCT00926380 Denosumab, Teriparatide or Both for the Treatment of Postmenopausal Osteoporosis | Osteoporosis | P2 | Completed | 94 | RCT, Open-label | denosumab, teriparatide |
| NCT01502982 Dose Dense Chemotherapy and Rituximab for Young High Risk Diffuse Large B-Cell Lymphoma Patients (CRY-04) | Diffuse Large B-Cell Lymphoma | P2 | Completed | 160 | Open-label | R-CHOEP14x6+HD-AraC+HD-Mtx |
| NCT00005960 Combination Chemotherapy in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy | Pain, Prostate Cancer | P2 | Unknown | — | — | filgrastim, cyclophosphamide, docetaxel, doxorubicin hydrochloride |
| NCT00695370 Evaluation of Pegfilgrastim for Stem Cell Mobilization in Children | Solid Malignancies | P2 | Terminated | 30 | Open-label | Pegfilgrastim (drug) |
| NCT01439880 Open Label Study of Long Term Evaluation Against LDL-C Trial | Hypercholesterolemia | P2 | Completed | 1,324 | RCT, Open-label | Evolocumab |
| NCT00958386 Safety and Efficacy Study of Panitumumab+Irinotecan in Patients Wild-Type (WT) KRAS Metastatic Colorectal Cancer Refractory to Irinotecan Based Chemotherapy (SPECTRA) | Metastatic Colorectal Cancer | P2 | Completed | 61 | Open-label | Panitumumab+irinotecan |
| NCT00038298 A Rheumatoid Arthritis (RA) Study Treating Signs and Symptoms of RA in People With RA & Receiving Methotrexate | Rheumatoid Arthritis | P2 | Completed | 53 | RCT, Double-blind | Placebo, AMG 719, AGM 719, AMG 719, placebo to AMG 719 |
| NCT00894504 Panitumumab, Gemcitabine and Carboplatin in Triple-Negative Metastatic Breast Cancer | Metastatic Breast Cancer | P2 | Completed | 71 | Open-label | Panitumumab, Carboplatin, Gemcitabine |
| NCT00049985 Heart Failure and Anemia | Heart Failure, Anemia | P2 | Completed | 300 | RCT, Double-blind | Darbepoetin Alfa |
| NCT00757172 Panitumumab, Docetaxel, Cisplatin, Radiation Therapy, and Surgery in Treating Patients With Newly Diagnosed, Locally Advanced Esophageal Cancer or Cancer of the Gastroesophageal Junction | Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer | P2 | Completed | 70 | Open-label | panitumumab, cisplatin, docetaxel |
| NCT03776058 Safety, Tolerability, and Clinical Effects of Twice-daily Doses of Cinacalcet (AMG 073) in Adults With Primary Hyperparathyroidism (HPT) | Primary Hyperparathyroidism | P2 | Completed | 10 | RCT, Double-blind | Cinacalcet, Placebo |
| NCT00836277 Phase II Study of Irinotecan and Panitumumab | Esophageal Cancer | P2 | Completed | 24 | Open-label | Panitumumab, Irinotecan |
| NCT01264328 Study of the Combination of Panitumumab With Paclitaxel as First-line Treatment of Subjects With Head and Neck Cancer | Head and Neck Cancer | P2 | Completed | 40 | Open-label | Panitumumab + paclitaxel |
| NCT00100477 Use of Topotecan in Patients With Refractory Acute Leukemia | Non-Hodgkin's Lymphoma, Leukemia | P2 | Completed | 10 | — | Topotecan, Mitozantrone, Etoposide |
| NCT03298412 Effect of Blinatumomab on Minimal Residual Disease (MRD) in Diffuse Large B-Cell Lymphoma (DLBCL) Subjects Post Autologous Hematopoietic Stem Cell Transplantation (aHSCT) | High-risk Diffuse Large B-cell Lymphoma | P2 | Terminated | 10 | Open-label | Blinatumomab |
| NCT01242917 A Study to Evaluate the Safety and Efficacy of CCX354-C in Subjects With Rheumatoid Arthritis Partially Responsive to Methotrexate Therapy | Rheumatoid Arthritis | P2 | Completed | 159 | RCT, Double-blind | CCX-354-C, Placebo, CCX354-C |
| NCT00369070 A Phase 2 Trial of AMG 706 or Bevacizumab in Combination With Chemo for Advanced NSCLC | Advanced Non-squamous NSCLC | P2 | Terminated | 186 | RCT, Open-label | Bevacizumab, AMG 706, Paclitaxel, Carboplatin |
| NCT00436670 Phase II Study to Evaluate the Efficacy of AMG 317 | Asthma | P2 | Completed | 294 | RCT, Double-blind | AMG 317 75 mg, AMG 317 150 mg, AMG 317 300 mg, Placebo |
| NCT00547157 Radiotherapy Plus Panitumumab Compared to Chemoradiotherapy With Unresected, Locally Advanced Squamous Cell Carcinoma of the Head and Neck | Cancer, Head and Neck Cancer | P2 | Completed | 152 | RCT, Open-label | Panitumumab, Cisplatin |
| NCT00433875 Phase 2 AMG 714 in Rheumatoid Arthritis | Rheumatoid Arthritis | P2 | Completed | 180 | RCT, Double-blind | AMG 714 |
| NCT00467025 AMG 386, 20060159 Phase 2, RCC 1st Line in Combination With Sorafenib | Advanced Renal Cell Carcinoma | P2 | Completed | 152 | RCT, Double-blind | AMG 386, Sorafenib, AMG 386 placebo IV |
| NCT07301424 Subcutaneous Blinatumomab Plus Ponatinib for BCR-ABL+ B-ALL | Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+), BCR-ABL Positive Acute Lymphoblastic Leukemia | P2 | Not Yet Recruiting | 80 | Open-label | Treatment with blinatumomab given subcutaneously. |
| NCT02807883 Blinatumomab Maintenance Following Allogeneic Hematopoietic Cell Transplantation for Patients With Acute Lymphoblastic Leukemia | Acute Lymphoblastic Leukemia | P2 | Completed | 23 | Open-label | Blinatumomab |
| NCT00086086 Subcutaneous (SC) Darbepoetin Alfa in Subjects With Symptomatic Congestive Heart Failure (CHF) & Anemia | Congestive Heart Failure, Anemia | P2 | Completed | 150 | RCT, Double-blind | Darbepoetin Alfa |
| NCT00586443 BEP Study Phase I (Bevacizumab, Everolimus, Panitumumab) | Solid Tumors | P1 | Completed | 56 | Open-label | bevacizumab, everolimus, panitumumab |
| NCT01660750 A Safety Study of Carfilzomib, Cyclophosphamide & Dexamethasone Prior to ASCT in Patients With Newly Diagnosed Myeloma | Multiple Myeloma | P1 | Completed | 29 | Open-label | Carfilzomib, Cyclophosphamide, Dexamethasone |
| NCT04293094 Study of AMG 650 in Adult Participants With Advanced Solid Tumors | Advanced Solid Tumors | P1 | Completed | 66 | Open-label | AMG 650 |
| NCT05480865 SHP2 Inhibitor BBP-398 in Combination With Sotorasib in Patients With Advanced Solid Tumors and a KRAS-G12C Mutation | Solid Tumor, Adult, Metastatic Solid Tumor | P1 | Terminated | 28 | RCT, Open-label | BBP-398, sotorasib |
| NCT00007813 Peripheral Stem Cell Transplantation Plus Chemotherapy in Treating Patients With Malignant Solid Tumors | Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor | P1 | Completed | 21 | Open-label | filgrastim, carboplatin, cyclophosphamide, etoposide |
| NCT00986895 A Study of Glyceryl Tri-(4-phenylbutyrate) Administered Orally as a Single Dose, and Twice Daily for Seven Consecutive Days to Subjects With Hepatic Impairment With Cirrhosis and to a Control Group | Hepatic Encephalopathy, Urea Cycle Disorders | P1 | Completed | 32 | Open-label | HPN-100 |
| NCT00977600 A Study of Glyceryl Tri-(4-phenylbutyrate) (GT4P) | Healthy | P1 | Completed | 24 | RCT, Open-label | HPN-100, Ammonul, Buphenyl |
| NCT03797261 A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic Malignancies | Acute Myeloid Leukemia, Non-Hodgkin's Lymphoma | P1 | Terminated | 9 | Open-label | Venetoclax, AMG 176 |
| NCT01549431 Study of the Combination of Panobinostat & Carfilzomib in Patients With Relapsed &/or Refractory Multiple Myeloma | Multiple Myeloma | P1 | Completed | 32 | Open-label | Panobinostat, Carfilzomib, Dexamethasone |
| NCT01789242 A Safety Study of Carfilzomib in Patients With Previously-Treated Systemic Light Chain Amyloidosis | Amyloidosis, Systemic Light Chain Amyloidosis | P1 | Completed | 32 | Open-label | Carfilzomib, Dexamethasone |
| NCT00879385 KRAS Wild-type Metastatic Colorectal Cancer Trial | Colorectal Cancer | P1 | Completed | 21 | Open-label | Dacogen™ (decitabine), Vectibix® (panitumumab) |
| NCT03340766 Study Investigating the Safety and Efficacy of Blinatumomab in Combination With Pembrolizumab in Adults With Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL) | Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL) | P1 | Completed | 31 | Open-label | Blinatumomab, Pembrolizumab |
| NCT01949545 Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Advanced Malignancies and Hepatic Impairment | Solid Tumors, Hematologic Malignancies | P1 | Completed | 46 | Open-label | Carfilzomib |
| NCT00322400 Phase1b to Evaluate Safety of AMG706 in Combination With Paclitaxel or Docetaxel for Breast Cancer | Locally Recurrent and Metastatic Breast Cancer | P1 | Completed | 46 | Open-label | Docetaxel, Paclitaxel, AMG 706 |
| NCT02391259 A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of AMG 557 in Subjects With Systemic Lupus Erythematosus | Systemic Lupus Erythematosus | P1 | Completed | 57 | RCT, Double-blind | AMG 557, Placebo |
| NCT02103283 A Phase 1, Open-Label Study of Teprotumumab in Patients With Diabetic Macular Edema (DME) | Diabetic Macular Edema | P1 | Completed | 5 | Open-label | Teprotumumab |
| NCT02756845 Study of Talimogene Laherparepvec In Children With Advanced Non CNS Tumors | Advanced Non CNS Tumors | P1 | Completed | 15 | Open-label | Talimogene Laherparepvec |
| NCT06563856 A Study of TEPEZZA Subcutaneous Administration in Healthy Adults | Bioavailability, Bioequivalence | P1 | Completed | 37 | Open-label | TEPEZZA, EDP |
| NCT01980589 A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Subjects | Multiple Myeloma | P1 | Completed | 22 | Open-label | Carfilzomib, Cyclophosphamide, Dexamethasone |
| NCT07422285 Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Dose | Healthy Participants, Pharmacokinetics | P1 | Completed | 405 | RCT, Open-label | Evolocumab Drug Substance A, Evolocumab Drug Substance B |
| NCT05913115 A Study Evaluating Safety and Pharmacokinetics of FPA144 in Japanese Patients With Advanced Gastric or Gastroesophageal Cancer | Gastric or Gastroesophageal Cancer | P1 | Completed | 6 | Open-label | FPA144 |
| NCT06910709 Single and Multiple Ascending Dose Study of AMG 378 in Healthy Participants | Healthy Volunteers | P1 | Terminated | 48 | RCT, Double-blind | AMG 378, Placebo |
| NCT01688739 Ascending Single Doses of Erenumab (AMG 334) in Healthy Adults and Migraine Patients | Migraine | P1 | Completed | 61 | RCT, Double-blind | Erenumab, Placebo |
| NCT04987333 Study of Efavaleukin Alfa in Healthy Chinese, Japanese, and Caucasian Participants | Inflammatory Diseases | P1 | Completed | 32 | Open-label | Efavaleukin alfa |
| NCT01949532 Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Multiple Myeloma and Renal Disease | Relapsed Multiple Myeloma, End-stage Renal Disease | P1 | Completed | 26 | Open-label | Carfilzomib |
| NCT02961881 A Phase 1b Open-Label Study Investigating the Safety and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma | Non-Hodgkin's Lymphoma | P1 | Completed | 35 | Open-label | blinatumomab |
| NCT00040651 Safety and Value of Self Bone Marrow Transplants Following Chemotherapy in Scleroderma Patients | Scleroderma, Systemic Sclerosis | P1 | Terminated | 15 | Open-label | Fludarabine, Cyclophosphamide, Thymoglobulin |
| NCT04887064 Pharmacokinetics of Sotorasib in Healthy Participants and Participants With Moderate or Severe Hepatic Impairment | Hepatic Impairment | P1 | Completed | 20 | Open-label | Sotorasib |
| NCT06127940 K-SAB Trial - Sotorasib Followed by SBRT to 1-3 Lesions in Advanced NSCLC With KRASG12C Mutation | Non-small Cell Lung Cancer Metastatic | P1 | Unknown | 20 | Open-label | Temporary Stopping |
| NCT01497821 AMG 172 First in Human Study in Patients With Kidney Cancer | Renal Cell Adenocarcinoma, Clear Cell Renal Carcinoma | P1 | Completed | 37 | Open-label | AMG 172 |
| NCT01386866 Single Dose Study of [14C]-Labelled AMG 706 in Patients With Advanced Solid Tumors | Advanced Solid Tumors | P1 | Completed | 4 | Open-label | AMG 706 |
| NCT01634178 Effect of Food on the Pharmacokinetics of Apremilast (CC-10004) in Healthy Adults | Healthy Volunteer | P1 | Completed | 46 | RCT, Open-label | Apremilast |
| NCT07226778 Comparing the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous (SC) Presentations | Overweight, Obesity | P1 | Completed | 348 | RCT, Open-label | Maridebart Cafraglutide |
| NCT06131398 A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors | Advanced Solid Tumors | P1 | Completed | 77 | Open-label | AMG 355, Pembrolizumab |
| NCT01723514 Ascending Multiple-Doses of Erenumab (AMG 334) in Healthy Adults and in Migraine Patients | Migraine | P1 | Completed | 48 | RCT, Double-blind | Erenumab, Placebo |
| NCT00813384 A Phase 1 Study of AMG 208 in Subjects With Advanced Solid Tumors | Cancer, Oncology | P1 | Completed | 54 | Open-label | AMG 208 |
| NCT01999335 A Study of Oprozomib, Pomalidomide, and Dexamethasone in Adults With Primary Refractory or Relapsed and Refractory Multiple Myeloma | Multiple Myeloma | P1 | Terminated | 33 | Open-label | Oprozomib, Pomalidomide, Dexamethasone |
| NCT03156023 Multiple Ascending Doses of Rozibafusp Alfa (AMG 570) in Adults With Rheumatoid Arthritis | Rheumatoid Arthritis | P1 | Completed | 34 | RCT, Double-blind | Rozibafusp Alfa, Placebo |
| NCT01294397 Effects of Denosumab on the Pharmacokinetics of Etanercept | Postmenopausal, Osteopenia | P1 | Terminated | 19 | Open-label | Etanercept, Denosumab |
| NCT00635596 Phase I Study of MT110 in Lung Cancer (Adenocarcinoma and Small Cell), Gastric Cancer or Adenocarcinoma of the Gastro-Esophageal Junction, Colorectal Cancer, Breast Cancer, Hormone-Refractory Prostate Cancer, and Ovarian Cancer | Solid Tumors | P1 | Completed | 65 | Open-label | MT110 |
| NCT00513383 Panitumumab Chemoradiotherapy Chemotherapy for Squamous Cancer of the Head and Neck | Squamous Cell Carcinoma of the Head and Neck | P1 | Completed | 34 | Open-label | Panitumumab, Carboplatin, Paclitaxel, 5-Fluorouracil, Docetaxel, Cisplatin |
| NCT02675452 AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid Leukemia | Relapsed or Refractory Multiple Myeloma, Relapsed or Refractory Acute Myeloid Leukemia | P1 | Terminated | 141 | Open-label | AMG 176, Azacitidine, Itraconazole |
| NCT06438263 A Study to Evaluate Bioavailability of Rocatinlimab Autoinjector and Vial in Healthy Participants | Atopic Dermatitis | P1 | Completed | 231 | RCT, Open-label | Rocatinlimab, Rocatinlimab |
| NCT04362748 Study of AMG 256 in Adult Subjects With Advanced Solid Tumors | Advanced Solid Tumors | P1 | Completed | 34 | Open-label | AMG 256 |
| NCT02293109 Carfilzomib and Hyper-CVAD in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoma | Contiguous Stage II Adult Lymphoblastic Lymphoma, Noncontiguous Stage II Adult Lymphoblastic Lymphoma | P1 | Completed | 10 | Open-label | carfilzomib, cyclophosphamide, vincristine sulfate, doxorubicin hydrochloride, dexamethasone, methotrexate, cytarabine, leucovorin calcium, methylprednisolone, rituximab |
| NCT05045638 Effect of Coadministration of Sotorasib on the Pharmacokinetics of Rosuvastatin in Healthy Participants | Healthy Participants | P1 | Completed | 13 | Open-label | Rosuvastatin, Sotorasib |
| NCT00361634 Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) to Measure Response to Etanercept in Rheumatoid Arthritis | Rheumatoid Arthritis | P1 | Completed | 14 | Open-label | Etanercept |
| NCT03430687 Talimogene Laherparepvec in Treating Patients With Non-Muscle Invasive Bladder Transitional Cell Carcinoma | Stage 0 Bladder Urothelial Carcinoma AJCC v6 and v7, Stage 0a Bladder Urothelial Carcinoma AJCC v6 and v7 | P1 | Withdrawn | — | Open-label | Talimogene Laherparepvec |
| NCT02618967 Single Ascending Dose Study of AMG 570 in Healthy Subjects | Systemic Lupus Erythematosus | P1 | Completed | 56 | RCT, Double-blind | AMG 570, AMG 570 Matching Placebo |
| NCT03757130 Multiple Ascending Dose Study of AMG 598 in Adults With Obesity | Obesity | P1 | Completed | 50 | RCT, Double-blind | AMG 598, Placebo, Liraglutide |
| NCT02054572 Pharmacokinetics and Excretion of [¹⁴C]Etelcalcetide (AMG 416) in Patients With End Stage Renal Disease (ESRD) Receiving Dialysis | Secondary Hyperparathyroidism in Patients With ESRD on Hemodialysis | P1 | Completed | 6 | Open-label | [¹⁴C]Etelcalcetide |
| NCT02170337 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 282 in Healthy Subjects and Subjects With Chronic Rhinosinusitis With Nasal Polyps | Chronic Rhinosinusitis With Nasal Polyps | P1 | Completed | 41 | RCT, Double-blind | AMG 282, Placebo |
| NCT02099461 Effect of Denosumab on Cellular Biomarkers in the Human Breast | Healthy Volunteer, Female, Breast | P1 | Completed | 82 | RCT, Open-label | Denosumab |
| NCT00448786 Effect of Different Doses of AMG 706 on the Gallbladder in Advanced Solid Tumors | Solid Tumors | P1 | Completed | 49 | RCT, Open-label | AMG 706, AMG 706, AMG 706 |
| NCT01510951 Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of AMG 811 in Subjects With Psoriasis | Psoriasis | P1 | Completed | 9 | RCT, Double-blind | AMG 811 or Placebo |
| NCT05056246 Study of AMG 133 Administered Subcutaneously in Healthy Japanese and Caucasian Participants | Healthy Participants | P1 | Completed | 34 | RCT, Open-label | AMG 133 |
| NCT00002255 An Open-Label Phase I/II Study of Recombinant Granulocyte Colony Stimulating Factor (r-metHuG-CSF) and Recombinant Erythropoietin (rHuEPO) Given Subcutaneously Along With Zidovudine (AZT) to Patients With the Acquired Immune Deficiency Syndrome (AIDS) or Severe AIDS-Related Complex (ARC) | HIV Infections | P1 | Completed | — | Open-label | Filgrastim, Epoetin alfa, Zidovudine |
| NCT04478708 Single and Multiple Ascending Dose Study of AMG 133 in Participants With Obesity | Obesity | P1 | Completed | 110 | RCT, Double-blind | maridebart cafraglutide, Placebo |
| NCT00102830 Study Evaluating AMG 386 in Adult Patients With Advanced Solid Tumors | Tumors | P1 | Completed | — | — | AMG 386 |
| NCT05988008 A Study of CCX168 in Japanese and Caucasian Healthy Adult Males | Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis | P1 | Completed | 80 | RCT, Single-blind | CCX168, Placebo |
| NCT07717814 A Trial to Assess Bioavailability of AMG 133 in Participants With Overweight or Obesity | Overweight and Obesity | P1 | Completed | 154 | RCT, Open-label | AMG 133 (frozen liquid), AMG 133 (liquid) |
| NCT07545226 Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Dose. | Healthy Participants | P1 | Completed | 405 | RCT, Open-label | Evolocumab Drug Substance A (Test), Evolocumab Drug Substance B (Reference) |
| NCT00756860 A Phase 1 Multiple Dose Study to Compare the Effects of AMG 223 and Sevelamer HCL (Renagel®) | Healthy Volunteers | P1 | Completed | 66 | RCT, Open-label | AMG 223, Renagel® (sevelamer hydrochloride) |
| NCT02504476 Multiple Ascending Dose Study on Safety, Tolerability, and Pharmacokinetics of AMG 581 in Healthy Subjects or Subjects With Schizophrenia or Schizoaffective | Schizophrenia or Schizoaffective Disorder | P1 | Completed | 52 | RCT, Double-blind | AMG 581, Placebo, Midazolam |
| NCT02275156 Estimation Study to Assess the Effect of Severe Renal Impairment and End-stage Renal Disease Hemodialysis on the Pharmacokinetics of Evolocumab | Hyperlipidemia, Mixed Dyslipidemia | P1 | Completed | 18 | Open-label | Evolocumab |
| NCT04478695 Study of AMG 330 in Combination With Pembrolizumab in Adult With Relapsed or Refractory Acute Myeloid Leukemia | Relapsed or Refractory Acute Myeloid Leukemia | P1 | Terminated | 1 | Open-label | AMG 330, Pembrolizumab |
| NCT00150462 Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies | Waldenstrom's Macroglobulinemia, Non-Hodgkin's Lymphoma | P1 | Completed | 48 | Open-label | Carfilzomib, Dexamethasone |
| NCT01212380 Study of Carfilzomib in Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) or Prolymphocytic Leukemia (PLL) | B-cell Chronic Lymphocytic Leukemia, Hematopoietic/Lymphoid Cancer | P1 | Completed | 21 | Open-label | carfilzomib |
| NCT03465540 Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies | Multiple Myeloma, Acute Myeloid Leukemia | P1 | Terminated | 24 | Open-label | AMG 397, Dexamethasone, Azacitidine |
| NCT01300026 AMG 319 Lymphoid Malignancy FIH | Cancer, Chronic Lymphocytic Leukemia | P1 | Completed | 28 | Open-label | AMG 319 |
| NCT01405963 Double-blind, Multiple Dose Study of Tezepelumab (AMG 157) in Adults With Mild Atopic Asthma | Asthma | P1 | Completed | 31 | RCT, Double-blind | Placebo, Tezepelumab |
| NCT01926665 Carfilzomib Consolidation Therapy After Autologous Stem Cell Transplantation (ASCT) for Mantle Cell Lymphoma (MCL), T-cell Lymphoma (TCL), and Diffuse Large B-Cell Lymphoma (DLBCL) | Lymphoma | P1 | Completed | 2 | Open-label | Carfilzomib, Dexamethasone |
| NCT01122199 Study of RAD001 + AMG479 for Patients With Advanced Solid Tumors | Neoplasm Metastases | P1 | Completed | 27 | Open-label | RAD001 + AMG479 |
| NCT00112385 A Pilot Study of Etanercept in Dermatomyositis | Dermatomyositis | P1 | Completed | 16 | RCT, Double-blind | Etanercept, Placebo |
| NCT00101894 Safety of AMG 706 Plus Panitumumab Plus Chemotherapy in the Treatment of Subjects With Metastatic Colorectal Cancer | Rectal Cancer, Colon Cancer | P1 | Completed | 119 | Open-label | FOLFOX-4, AMG 706, Panitumumab (Part 1a only), FOLFIRI |
| NCT04673630 Study to Evaluate the Pharmacokinetics of Tezepelumab in Children With Asthma | Asthma | P1 | Completed | 18 | Open-label | Tezepelumab |
| NCT04545554 Study to Evaluate Romosozumab in Children and Adolescents With Osteogenesis Imperfecta | Osteogenesis Imperfecta | P1 | Completed | 25 | Open-label | Romosozumab |
| NCT02520427 A Phase 1 Study of AMG 330 in Subjects With Myeloid Malignancies | Relapsed/Refractory AML, Minimal Residual Disease Positive AML | P1 | Terminated | 95 | Open-label | AMG 330 |
| NCT00840333 "Safety, Tolerability and Pharmacokinetics of MP-376 Administered for 14 Days to Stable Pediatric (CF) Patients" | Cystic Fibrosis | P1 | Completed | 27 | RCT, Open-label | MP-376 (Levofloxacin solution for Inhalation) |
| NCT02833857 A Single-dose Study in Paediatric Patients Aged 2 to Less Than 18 Years With Secondary Hyperparathyroidism (sHPT) Receiving Haemodialysis | Chronic Kidney Disease, Secondary Hyperparathyroidism | P1 | Completed | 11 | Open-label | Etelcalcetide |
| NCT00997022 Trial of Sorafenib in Hepatocellular Cancer (HCC) Transplant Patients | Hepatocellular Cancer | P1 | Completed | 14 | Open-label | Sorafenib |
| NCT06004947 A Study in Healthy Volunteers to Evaluate the Drug-Drug Interaction Potential of CCX168 With Concomitant Medications | Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis | P1 | Completed | 32 | Open-label | CCX168, Midazolam, Celecoxib, Itraconazole, Rifampicin |
| NCT04524455 Blinatumomab in Combination With AMG 404 for the Treatment of Adults With Relapsed or Refractory B Cell Precursor ALL | Acute Lymphoblastic Leukemia | P1 | Completed | 17 | Open-label | Blinatumomab, AMG 404, Dexamethasone Premedication |
| NCT04478994 A Study With TEPEZZA in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc) | Diffuse Cutaneous Systemic Sclerosis | P1 | Terminated | 3 | RCT, Double-blind | TEPEZZA |
| NCT00757042 Safety Study of Tezepelumab (AMG 157) in Healthy Adults and Adults With Atopic Dermatitis | Atopic Dermatitis, Healthy Volunteers | P1 | Completed | 78 | RCT, Double-blind | Tezepelumab, Placebo |
| NCT01588509 Transition From Alendronate to Romosozumab (AMG 785) | Osteoporosis | P1 | Completed | 60 | RCT, Open-label | Romosozumab |
| NCT01890109 Study of Erenumab (AMG 334) in Women With Hot Flashes | Vasomotor Symptoms; Hot Flashes | P1 | Completed | 103 | RCT, Double-blind | Erenumab, Placebo |
| NCT03318809 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 986 Administered Orally to Healthy Volunteers and Participants With Severely Impaired Renal Function | Heart Failure | P1 | Completed | 12 | Open-label | AMG 986 |
| NCT00091806 Two Dose Schedules of Panitumumab in Subjects With Advanced Solid Tumors | Tumors, Oncology | P1 | Completed | 86 | Open-label | panitumumab (ABX-EGF), Panitumumab |
| NCT07429045 A Trial to Assess the Effect of Kidney Impairment on How AMG 133 is Absorbed, Broken Down, and Eliminated by the Body | Overweight and Obesity | P1 | Completed | 44 | Open-label | AMG 133 |
| NCT02318407 A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 403 in Subjects With Osteoarthritis Knee Pain | Osteoarthritis | P1 | Completed | 24 | RCT, Double-blind | AMG 403, Placebo |
| NCT02741310 Study to Evaluate the Effect of Erenumab on Blood Pressure When Given Concomitantly With Subcutaneous Sumatriptan | Healthy Subjects | P1 | Completed | 34 | RCT, Double-blind | Placebo, Sumatriptan, Erenumab |
| NCT01953341 Single-Ascending Dose Study of AMG 333 in Healthy Subjects and Subjects With Migraines | Migraine | P1 | Completed | 74 | RCT, Double-blind | AMG 333, Placebo |
| NCT00972179 Safety Study of Tezepelumab (AMG 157) in Healthy Adults | Healthy Volunteers | P1 | Completed | 49 | RCT, Double-blind | Placebo, Tezepelumab |
| NCT05598281 Study to Evaluate the Effect of AMG 510 on the Pharmacokinetics (PK) of Digoxin in Healthy Participants | Healthy Participants | P1 | Completed | 14 | Open-label | AMG 510, Digoxin |
| NCT01290042 Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181. | Ulcerative Colitis, Crohn's Disease | P1 | Completed | 43 | RCT, Double-blind | AMG 181 |
| NCT00902356 A First-in-human Study Evaluating AMG 167 in Healthy Men and Postmenopausal Women | Osteopenia | P1 | Completed | 69 | RCT, Double-blind | AMG 167, Placebo |
| NCT01493518 Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of AMG 557 in Adults With Psoriasis | Psoriasis | P1 | Terminated | 6 | RCT, Double-blind | AMG 557 or PLACEBO |
| NCT05578859 A Study of the Absorption, Metabolism, and Excretion of [14C]-AMG 510 Following a Single Oral Dose in Healthy Male Subjects | Healthy Subjects | P1 | Completed | 8 | Open-label | AMG 510 |
| NCT00186602 Does a Peer Navigator Improve Quality of Life at Diagnosis for Women With Breast Cancer? | Breast Cancer | Completed | — | — | — | |
| NCT01139918 Exploratory Study on Quality of Life in Patient With Moderate Psoriasis and Moderate Psoriatic Arthritis | Psoriatic Arthritis, Psoriasis | Completed | 105 | — | — | |
| NCT05360225 Testing of DNA Extracted From Tumor Tissue Biopsy Samples Using Therascreen KRAS RGQ PCR Kit | Non Small Cell Lung Cancer | Completed | 5,000 | — | — | |
| NCT02520362 Denosumab Safety Assessment in Multiple Observational Databases | Osteoporosis | Completed | 517,991 | — | denosumab, bisphosphonate | |
| NCT05245851 Clinical Deployment and Validation of Rho | Low Bone Density | N/A | Completed | 1,146 | Open-label | — |
| NCT02922179 Descriptive Analysis of Long- and Intermediate-Acting Insulin in Adult Diabetics | Diabetes | Completed | 103,951 | — | Long- and intermediate- acting insulins | |
| NCT02921191 Descriptive Analysis of G-CSF Use in Patients With Breast Cancer, Lung Cancer, or Lymphoma Treated | Breast Cancer, Lung Cancer | Completed | 57,725 | — | filgrastim, TBO-filgrastim or pegfilgrastim | |
| NCT02922192 Incidence of Hospitalizations for Serious Infections in Patients Receiving Biologic Anti-Inflammatories for Rheumatologic, Psoriatic, and Gastrointestinal Conditions: A Descriptive Analysis | Rheumatoid Arthritis, Inflammatory Bowel Disease | Completed | 90,360 | — | TNF-α antagonists, non-TNFs, DMARD non-biologics | |
| NCT05826756 Project PEER: Understanding the Lung Cancer Patient ExperiEnce in the Real-World Setting | Lung Cancer Patients, Caregivers | Unknown | 1,300 | — | — | |
| NCT06585189 CARE Initiative: Real-world Emulation of the KEYNOTE-189 Trial [DS4] | Metastatic Non Small Cell Lung Cancer | Completed | 304 | — | Pembrolizumab, Pemetrexed, Cisplatin, Carboplatin | |
| NCT05347745 Therascreen® KRAS RGQ PCR Kit | Colo-rectal Cancer | N/A | Completed | 219 | Open-label | — |
| NCT05347797 Clinical Study Testing DNA Extracted From Tumour Tissue Biopsy Samples, Using the Therascreen® KRAS RGQ PCR Kit | Non-small Cell Lung Cancer | N/A | Completed | 495 | Open-label | — |
| NCT06607393 CARE Initiative: Real-world Emulation of the KEYNOTE-189 Trial [DS3] | Metastatic Nonsmall Cell Lung Cancer | Completed | 851 | — | Pembrolizumab, Pemetrexed, Cisplatin, Carboplatin | |
| NCT06607601 CARE Initiative: Real-world Emulation of the PALOMA-2 Trial | Metastatic Breast Cancer | Completed | 724 | — | Palbociclib, Letrozole | |
| NCT05348187 Clinical Performance Study Protocol for Therascreen® KRAS RGQ PCR Kit | Non-Small Cell Lung Cancer, Colorectal Cancer | N/A | Completed | 309 | Open-label | — |
| NCT00472290 Evaluating the Safety of Long Term Dosing of Romiplostim (Formerly AMG 531) in Thrombocytopenic Subjects With Myelodysplastic Syndromes (MDS) | Hematology, MDS | N/A | Completed | 72 | Open-label | Romiplostim (formerly AMG 531) |
| NCT01948427 Observational Study That Will Collect Information on Patients With Urea Cycle Disorders (UCDs) | Urea Cycle Disorder | Terminated | 203 | — | — | |
| NCT02808403 Long Term Post Marketing Specified Drug Use Result Survey for Evolocumab in Japan | Hypercholesterolemia, Familial Hypercholesterolemia | Completed | 6,000 | — | — | |
| NCT05891119 Study to Investigate the Effect of Rocatinlimab (AMG 451) on the Pharmacokinetics of Multiple Cytochrome P450 (CYP450) Substrates in Participants With Moderate to Severe Atopic Dermatitis | Atopic Dermatitis | Early P1 | Completed | 21 | Open-label | Metoprolol, Midazolam, Warfarin, Omeprazole, Rocatinlimab |
| NCT03970902 Quality of Life in Postmenopausal Women With Osteoporosis | Postmenopausal Osteoporosis | Completed | 239 | — | — | |
| NCT01122095 Cross-sectional Evaluation of Biological Markers of Cardiovascular Disease in Children and Adolescents With Psoriasis | Psoriasis, Obesity | Unknown | 100 | — | — | |
| NCT03691311 Biomarker Study of the Antitumoral Activity of Denosumab in the Pre- Operative Setting of Early Breast Cancer | Breast Neoplasm Female, Stage I Breast Cancer | Early P1 | Unknown | 60 | RCT, Open-label | Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA] |
| NCT00413400 Study of TNF-Antagonism in the Metabolic Syndrome (II) | Metabolic Syndrome | N/A | Completed | 40 | RCT, Double-blind | Etanercept, Placebo |
| NCT00615901 Dose Dense Adjuvant CMF (Cyclophosphamide, Methotrexate, Fluorouracil) at 14 and 10-11 Day Intervals for Women With Early Stage Breast Cancer | Breast Cancer | N/A | Completed | 38 | Open-label | cyclophosphamide, methotrexate, fluorouracil, PEG-filgrastim |
| NCT02783651 An Study of Patients With Ph- Chromosome-negative Relapsed or Refractory Acute Lymphoblastic Leukemia in the US | Relapsed/Refractory Acute Lymphoblastic Leukemia | Completed | 212 | — | — | |
| NCT00002037 Evaluation of the Therapeutic Benefit of r-metHuIFN- Gamma in AIDS Patients With Disseminated Mycobacterium Avium-Intracellulare (MAI) Infection: A Multi-Centered Pilot Study | Mycobacterium Avium-Intracellulare Infection, HIV Infections | N/A | Completed | 15 | Open-label | Trifluridine |
| NCT03096990 A Study of the Real-life Management of Psoriatic Arthritis Patients Treated With Otezla® (Apremilast) in Belgium | Arthritis, Psoriatic | Completed | 106 | — | apremilast | |
| NCT04645420 Molecular Effects of Apremilast in the Synovium of Psoriatic Arthritis Patients | Psoriatic Arthritis | N/A | Completed | 19 | Open-label | — |
| NCT00283621 Aranesp and Neulasta in Patients With Sarcoma Receiving Adriamycin and Ifosfamide | Sarcoma | N/A | Completed | 51 | Open-label | Aranesp (darbepoetin alfa), Neulasta (pegfilgrastim), Adriamycin, Ifosfamide |
| NCT04220164 Observation of Blood Lipid Outcomes in Lipid Clinic | Dyslipidemias | Unknown | 500 | — | — | |
| NCT03139630 COPANA - A09 PCSK 9 Substudy: Impact of Protease Inhibitors on PCSK9 Levels in Naive HIV-Infected Patients | HIV Seropositivity, Dyslipidemias | Completed | 193 | — | — | |
| NCT01842776 Care Transitions in Renal Disease Patients | Renal Disease | Unknown | 3,300 | — | — | |
| NCT03398954 a Prospective Pilot Study of Screening Out Rate and Clinical Management of Familial Hypercholesterolemia | Familial Hypercholesterolemia | Unknown | 1,128 | — | — | |
| NCT02851732 Brazilian inteRvention to Increase eviDence usaGe in practicE - Cardiovascular Prevention | Cardiovascular Diseases | N/A | Completed | 1,623 | RCT, Single-blind | — |
| NCT01666106 Osteonecrosis of the Jaw (ONJ) Case Registry | Osteonecrosis of the Jaw | Completed | 327 | — | — | |
| NCT01191385 GIDEON Non-Nexavar Arm - HCC Patients Who Are Treated With Any Therapy Other Than Nexavar at Individual Study Start | Carcinoma, Hepatocellular | Withdrawn | — | — | Any treatment for unresectable HCC as chosen by the physician | |
| NCT04478227 TPO-Mimetic Use in Children for Hematopoietic Failure | Bone Marrow Failure Disorders, Aplastic Anemia | Early P1 | Completed | 15 | Open-label | Romiplostim |
| NCT00861224 Effects of Long-term Dosing of AMG 531 on Bone Marrow Morphology | Idiopathic Thrombocytopenic Purpura | Completed | 10 | — | — | |
| NCT05256446 AMG 701 Expanded Access Program | NO_LONGER_AVAILABLE | — | — | AMG 701 | ||
| NCT05171270 AsseSSing Impact in pSoriatic Treatment | Psoriatic Arthritis | Completed | 503 | — | — | |
| NCT03224819 Study of Emerfetamab (AMG 673) in Adults With Relapsed/Refractory Acute Myeloid Leukemia (AML) | Acute Myeloid Leukemia | Early P1 | Terminated | 46 | Open-label | Emerfetamab |
| NCT01541072 Lymphocyte Reconstitution After Administration of Pegfilgrastim Versus Filgrastim After Peripheral Stem Cell Transplantation | Non Hodgkin Lymphoma | N/A | Terminated | 34 | RCT, Open-label | Pegfilgrastim, Filgrastim |
| NCT00355407 Darbepoetin Alfa (Aranesp) Following Allogeneic Stem Cell Transplantation | Hematologic Malignancies | N/A | Completed | 31 | Open-label | Darbepoetin alfa |
| NCT00189501 A Multi-Center, Observational Registry of Subjects With Secondary Hyperparathyroidism (HPT) and Chronic Kidney Disease (CKD) | Nephrology | Completed | 1,000 | — | Sensipar® | |
| NCT00930592 Peds Metabolic Syndrome in Psoriasis | Psoriasis, Metabolic Syndrome | Completed | 42 | — | — | |
| NCT00002281 A Study of Granulocyte Colony-Stimulating Factor Plus Recombinant Erythropoietin Plus Zidovudine in Patients With AIDS or AIDS-Related Complex | HIV Infections, Cytopenias | N/A | Completed | 24 | Open-label | Filgrastim, Epoetin alfa, Zidovudine |
| NCT05669040 mHealth to Improve the Experience, Adherence to Drug Treatment and Positive Mental Health | Fracture of Femur | N/A | Unknown | 278 | Single-blind | — |
| NCT00477191 Effects of TNF-alpha Antagonism (Etanercept) in Patients With the Metabolic Syndrome and Psoriasis | Psoriasis, Metabolic Syndrome | N/A | Terminated | 18 | Open-label | Etanercept |
| NCT02287610 A Non-Interventional Study of RAYOS in Adult Patients With Rheumatoid Arthritis | Rheumatoid Arthritis | Completed | 75 | — | RAYOS (delayed-release prednisone) | |
| NCT02435147 Longitudinal Effects of Denosumab on Trabecular Bone Score and Femur Strength Index | Osteoporosis, Bone Fracture | Completed | 86 | — | denosumab | |
| NCT03097003 A Study of the Real-life Management of Psoriasis Patients Treated With Otezla® (Apremilast) in Belgium | Psoriasis | Completed | 124 | — | Apremilast | |
| NCT00512499 Strategies to Treat Osteoporosis Following a Fragility Fracture | Osteoporosis, Fractures | N/A | Completed | 1,410 | RCT, Single-blind | — |
| NCT06576050 WeighT LOSS Surgery and Comprehensive Cardiometabolic Responses to to EXercise | Heart Failure, Obesity | Completed | 21 | — | — | |
| NCT01791361 Medical Records Review to Describe the Patterns of KRAS Testing and Vectibix Use in Europe | Metastatic Colorectal Cancer | Completed | 439 | — | — | |
| NCT07355894 Health Enhanced Artery Risk Tracking With Widespread Implementation and Screening Effort in ASCVD (HEARTWISE-ASCVD) | Atherosclerotic Cardiovascular Disease (ASCVD), Coronary Artery Calcification | N/A | Not Yet Recruiting | 120,000 | RCT, Open-label | — |
| NCT02626793 A Study of Otezla® in Patients With Plaque Psoriasis Under Routine Conditions | Psoriasis | Completed | 391 | — | — | |
| NCT05273047 RW Efficacy of Sotorasib in KRAS G12C-mutated Metastatic NSCLC | Nsclc, KRAS P.G12C | Unknown | 458 | — | — | |
| NCT00928408 PRIMARA: A Prospective Descriptive Observational Study to Review Mimpara (Cinacalcet) Use in Patients With Primary Hyperparathyroidism in Clinical Practice | Hyperparathyroidism, Primary | Completed | 305 | — | Cinacalcet | |
| NCT00617370 Dose-Dense Epirubicin and Cyclophosphamide (EC) Followed by Paclitaxel in Breast Cancer: Feasibility | Breast Cancer, Adenocarcinoma of the Breast | N/A | Completed | 38 | Open-label | epirubicin, cyclophosphamide, Paclitaxel, |
| NCT02303522 Historical Data Analysis of Complete Remission in Children With R/R Acute Lymphoblastic Leukemia (ALL) | B-cell Precursor Acute Lymphoblastic Leukemia (ALL) | Completed | 207 | — | — | |
| NCT02173171 Registry Study for Talimogene Laherparepvec | Any Tumor Type Eligible for Treatment With Talimogene Laherparepvec in Amgen or BioVEX-sponsored Clinical Trial | Completed | 185 | — | — | |
| NCT05542719 Mexican Registry of Dyslipidemia in Patients at High Risk and Very High Risk of Atherosclerotic Cardiovascular | Secondary Prevention, Cardiovascular Disease With Mention of Arteriosclerosis | Unknown | 13,166 | — | — | |
| NCT00802815 Double-blind, Randomized, Placebo-controlled Trial of Etanercept for 12 Months in Subjects With Inclusion Body Myositis | Inclusion Body Myositis | Early P1 | Completed | 20 | RCT, Double-blind | Etanercept |
| NCT06761703 A Study to Determine the Feasibility of Online Recruitment of People Using an Anti-Obesity Medication for Weight Loss | Obesity | Completed | 200 | — | — | |
| NCT07883564 Improving Implementation of Guideline-Recommended LDL-C Management in High-Risk Cardiovascular Patients | ASCVD | Not Yet Recruiting | 2,500 | — | — | |
| NCT02185911 Observational Study of Correction of Anaemia With Darbepoetin Alfa at QM Dosing Interval in Patients With CKD Not on Dialysis | Anaemia, Chronic Kidney Disease (CKD) | Completed | 308 | — | — | |
| NCT04654364 Lung Cancer Registry | Lung Cancer, NSCLC Stage IV | Completed | 290 | — | — | |
| NCT00115128 Open-Label Trial of Peripheral Blood Progenitor Cell (PBPC) Mobilization by Filgrastim in Normal Donors | Normal PBPC Donors | Completed | 309 | — | filgrastim | |
| NCT03091127 Real-world Use of Carfilzomib Among Multiple Myeloma Patients in Europe | Multiple Myeloma | Completed | 705 | — | — | |
| NCT03757013 A Study to Assess Benefits of Apremilast in Patients With Moderate to Severe Chronic Plaque Psoriasis Followed by Dermatologists Under Real Life Settings in France | Psoriasis | Completed | 453 | — | Apremilast | |
| NCT00094822 Pegfilgrastim Given Same Day As or Day After Carboplatin and Docetaxel in Advanced Metastatic Non-Small Cell Lung Cancer (NSCLC) | Lung Cancer, Non-Small Cell Lung Cancer | Completed | 90 | — | — | |
| NCT06140095 Studies to Gain Insight How the Drugs PCSK9-inhibitors and Statins Affect Cholesterol and Bile Acid Metabolism | Acute Metabolic Effects of Evolocumab and Atorvastatin | Early P1 | Unknown | 8 | Open-label | Evolocumab |
| NCT04197453 The Cardiovascular Multi-dimensional Observational Investigation of the Use of PCSK9 Inhibitors (cvMOBIUS) | ASCVD | Terminated | 752 | — | — | |
| NCT05495620 Long-term KRd in Relapsed and/or Refractory Multiple Myeloma | Multiple Myeloma in Relapse, Multiple Myeloma, Refractory | Unknown | 300 | — | Carfilzomib, Lenalidomide, Dexamethasone | |
| NCT07143513 Real World Evaluation of Sotorasib Among Chinese Non-Small Cell Lung Cancer Patients | Non-Small Cell Lung Cancer | Completed | 102 | — | Sotorasib | |
| NCT00398372 Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma Patients Receiving Antibody Treatment | Lymphoma, Non-Hodgkin, Lymphomas: Non-Hodgkin | N/A | Completed | 500 | Open-label | Rituximab, Epratuzumab |
| NCT01156090 A Retrospective Cohort Study of Infusion Reactions Due to Vectibix | Infusion Reaction | Completed | 141 | — | — | |
| NCT02740218 A Study of Real-World Experience of Psoriasis Patients Treated With Apremilast in Clinical Dermatology Practice | Psoriasis | Completed | 610 | — | — |